DEBING YANNICK (US)
STOYCHEVA ANTITSA (US)
RABOISSON PIERRE (US)
WO2020214728A1 | 2020-10-22 | |||
WO2019020070A1 | 2019-01-31 | |||
WO2019076310A1 | 2019-04-25 | |||
WO2020221816A1 | 2020-11-05 | |||
WO2020125729A1 | 2020-06-25 |
WHAT IS CLAIMED IS: 1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure: wherein: R1 is 3,4-disubstituted phenyl or trisubstituted phenyl, wherein each substitution group on the phenyl is independently selected from the group consisting of fluoro, chloro, bromo, –CHF2, –CF3, –CH3, –CN and –CŁ&+^^ R2 is –C(=O)R5; R3 is selected from the group consisting of a substituted phenyl, a substituted monocyclic heteroaryl and a substituted bicyclic heteroaryl; R4 is selected from the group consisting of –CHF2, –CH3, –cyclopropyl, an unsubstituted C1-4 hydroxyalkyl, an unsubstituted or substituted benzyl–O–CH2– and an unsubstituted or substituted monocyclic heterocyclyl–CH2–; R6 is an unsubstituted or a substituted 5- or 6-membered monocyclic heteroaryl comprising 1, 2 or 3 nitrogens, and optionally 1 or 2 heteroatoms selected from the group consisting of oxygen and sulfur, and when R6 is substituted, R6 is substituted with one or more substituents selected from the group consisting of halogen, an unsubstituted C1-4 alkyl, an unsubstituted C1-4 haloalkyl, an unsubstituted –O–C1-4 alkyl, amino and mono-C1-6 alkyl amine; R7 is selected from the group consisting of halogen, an unsubstituted C1-4 alkyl and an unsubstituted –O–C1-4 alkyl; and n is 0 or 1; or R6 is halogen; n is 1; and R7 is halogen; and provided that a compound of Formula (I) cannot be selected from the group consisting of: rac-(6S)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo- N-[(2-pyrazol-1-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo- N-[(2-pyrazol-1-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6S)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-N-[[2-(4- fluoropyrazol-1-yl)phenyl]methyl]-6-methyl-3-oxo-6,8-dihydro-5H-imidazo[1,5-a]pyrazine- 1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-N-[[2-(4- fluoropyrazol-1-yl)phenyl]methyl]-6-methyl-3-oxo-6,8-dihydro-5H-imidazo[1,5-a]pyrazine- 1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo- N-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1- carboxamide, rac-(6S)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo- N-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1- carboxamide, rac-(6R)-7-(4-bromo-3-cyano-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo- N-[(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6S)-7-(4-bromo-3-cyano-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo- N-[(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylphenyl)-N- [(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6S)-7-(4-bromo-3-chloro-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylphenyl)-N- [(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6R)-7-(4-bromo-3-cyano-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylphenyl)-N- [(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, and rac-(6S)-7-(4-bromo-3-cyano-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylphenyl)-N- [(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, or a pharmaceutically acceptable salt of any of the foregoing. 2. The compound of Claim 1, wherein R6 is selected from the group consisting of an unsubstituted or a substituted pyrazole, an unsubstituted or a substituted imidazole, an unsubstituted or a substituted oxazole, an unsubstituted or a substituted 1,3,4-oxadiazole, an unsubstituted or a substituted pyridine, an unsubstituted or a substituted pyrimidine, an unsubstituted or a substituted pyrazine, an unsubstituted or a substituted pyridazine and an unsubstituted or a substituted 1,2,4-triazine. , , 5. The compound of any one of Claims 1-4, wherein R5 is selected from the group consisting of: 6. The compound of Claim 5, wherein R5 is selected from the group consisting . 7. The compound of Claim 5, wherein R5 is selected from the group consisting of: 8. The compound of Claim 5, wherein R5 is selected from the group consisting and . 9. The compound of Claim 5, wherein R5 is 10. The compound of Claim 5, wherein R5 is selected from the group consisting 11. The compound of any one of Claims 1-10, wherein R1 is 3,4-disubstituted phenyl, wherein each substitution group on the phenyl is independently selected from the group consisting of fluoro, chloro, bromo, –CHF2, –CF3, –CH3, –CN and –CŁCH. 12. The compound of Claim 11, wherein R1 is selected from the group consisting . 13. The compound of Claim 12, wherein R1 is . 14. The compound of any one of Claims 1-10, wherein R1 is trisubstituted phenyl, wherein each substitution group on the phenyl is independently selected from the group consisting of fluoro, chloro, bromo, –CHF2, –CF3, –CH3, –CN and –CŁCH. 15. The compound of Claim 14, wherein the trisubstituted phenyl is a 3,4,5- trisubstituted phenyl. 16. The compound of Claim 15, wherein R1 is selected from the group consisting 17. The compound of any one of Claims 1-16, wherein at least one of the substitutions on R1 is selected from the group consisting of fluoro, chloro and bromo. 18. The compound of any one of Claims 1-17, wherein R4 is –CHF2. 19. The compound of any one of Claims 1-17, wherein R4 is –CH3. 20. The compound of any one of Claims 1-17, wherein R4 is –cyclopropyl. 21. The compound of any one of Claims 1-17, wherein R4 is an unsubstituted C1-4 hydroxyalkyl. 22. The compound of any one of Claims 1-17, wherein R4 is an unsubstituted or substituted benzyl–O–CH2–. 23. The compound of any one of Claims 1-17, wherein R4 is an unsubstituted or substituted monocyclic heterocyclyl–CH2–. 24. The compound of any one of Claims 18-23, wherein the compound has a structure selected from the group consisting of: 25. The compound of any one of Claims 1-24, wherein R3 is a substituted phenyl. 26. The compound of any one of Claims 1-24, wherein R3 is a substituted monocyclic heteroaryl. 27. The compound of any one of Claims 1-24, wherein R3 is a substituted bicyclic heteroaryl. 28. The compound of any one of Claims 1-24, wherein R3 is selected from the group consisting of: , , , , 29. The compound of any one of Claims 1-24, wherein R3 is selected from the group consisting of: , , , , , , , , 30. The compound of any one of Claims, 1 or 11-28, wherein R6 is halogen; n is 1; and R7 is halogen. 31. The compound of Claim 1 selected from the group consisting of: or a pharmaceutically acceptable salt of any of the foregoing. 32. The compound of Claim 1 selected from the group consisting of: , , , or a pharmaceutically acceptable salt of any of the foregoing. 33. The compound of Claim 1 selected from the group consisting of: or a pharmaceutically acceptable salt of any of the foregoing. 34. The compound of Claim 1 selected from the group consisting of: or a pharmaceutically acceptable salt of any of the foregoing. 35. A compound selected from the group consisting of: pharmaceutically acceptable salt of any of the foregoing. 36. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-33, or a pharmaceutically acceptable salt thereof, and excipient. 37. Use of the compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of hepatitis B. 38. Use of the compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of hepatitis D. 39. The use of any one of Claims 37-38, wherein the use further comprises the use of an additional agent selected from the group consisting of an interferon, a nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator. 40. The use of Claim 39, wherein the additional agent is selected from the group consisting of recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide, tenofovir disoproxil and a modified oligonucleotide selected from Nos. 1-392 of U.S. 2020/0147124 A1. 41. The use of Claim 40, wherein the additional agent is 5’mApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln( 5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrA psln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C psrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C 3’ (SEQ ID NO: 4), wherein mA is 2’-O- methyladenosine, ps is phosphorothioate, ln(5m)C is locked 5-methylcytidine, and rA is ribo- adenosine. 42. A compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, for use in treating hepatitis B. 43. A compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, for use in treating hepatitis D. 44. The compound of any one of Claims 42-43, wherein the compound is used in combination with an additional agents selected from the group consisting of an interferon, a nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator. 45. The compound of Claim 44, wherein the additional agent is selected from the group consisting of recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide, tenofovir disoproxil and a modified oligonucleotide selected from Nos. 1-392 of U.S. 2020/0147124 A1. 46. The compound of Claim 45, wherein the additional agent is 5’mApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln( 5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrA psln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C psrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C 3’ (SEQ ID NO: 4), wherein mA is 2’-O- methyladenosine, ps is phosphorothioate, ln(5m)C is locked 5-methylcytidine, and rA is ribo- adenosine. 47. A method for treating hepatitis B in a subject comprising administering to the subject in need thereof an effective amount of a compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, suffering from hepatitis B. 48. A method for treating hepatitis D in a subject comprising administering to the subject in need thereof an effective amount of a compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, suffering from hepatitis D. 49. The method of any one of Claims 47-48, further comprising administering an additional agent selected from the group consisting of an interferon, a nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator. 50. The method of Claim 49, wherein the additional agent is selected from the group consisting of recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide, tenofovir disoproxil and a modified oligonucleotide selected from Nos. 1-392 of U.S. 2020/0147124 A1. 51. The method of Claim 50, wherein the additional agent is 5’mApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln( 5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrA psln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C psrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C 3’ (SEQ ID NO: 4), wherein mA is 2’-O- methyladenosine, ps is phosphorothioate, ln(5m)C is locked 5-methylcytidine, and rA is ribo- adenosine. |
Additional e 3 xamples of R groups include the following: , ,
[0087] In some embodiments, R 4 can be –CHF 2 . In other embodiments, R 4 can be –CH 3 . In still other embodiments, R 4 can be –cyclopropyl. In yet still other embodiments, R 4 can be an unsubstituted C 1-4 hydroxyalkyl, such as –(CH 2 ) 1-4 –OH. In some embodiments, R 4 can be an unsubstituted benzyl–O–CH 2 –. In other embodiments, R 4 can be a substituted benzyl–O–CH 2 –. In still other embodiments, R 4 can be an unsubstituted monocyclic heterocyclyl–CH 2 –. In yet still other embodiments, R 4 can be a substituted monocyclic heterocyclyl–CH 2 –. The heterocyclyl of heterocyclyl–CH 2 – can be a 5- or 6- membered heterocyclyl that can include 1 or 2 heteroatoms selected from nitrogen (N), oxygen (O) and sulfur (S). Examples of suitable monocyclic heterocyclyls are described herein, and include an unsubstituted or a substituted morpholine. [0088] When R 4 is a substituent provided herein, a stereocenter may be formed. In some embodiments, the stereocenter that is formed can be in the (R)-configuration. In other embodiments, the stereocenter that is formed can be in the (S)-configuration. Compounds of Formula (I), along with pharmaceutically acceptable salts thereof, with a stereocenter at the carbon to which R 4 is attached can include Formula (Ia) and Formula (Ib). [0089] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be where R 1 can be 3,4-disubstituted phenyl or trisubstituted phenyl, wherein each substitution group on the phenyl can be independently selected from fluoro, chloro, bromo, –CHF 2 , –CF 3 , –CH 3 , –CN and –CŁ&+^^5 2 can be –C(=O)R 5 ; R 3 can
monocyclic heteroaryl comprising 1, 2 or 3 nitrogens, and optionally 1 or 2 heteroatoms selected from oxygen and sulfur, and when R 6 is substituted, R 6 can be substituted with one or more substituents selected from halogen, an unsubstituted C 1-4 alkyl, an unsubstituted –O– C 1-4 alkyl, amino and mono-C 1-6 alkyl amine; R 7 can be selected from halogen, an unsubstituted C 1-4 alkyl and an unsubstituted –O–C 1-4 alkyl; and n can be 0 or 1. [0090] In some embodiments, , a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be where R 1 can be – C(=O)R 5 , wherein R 5 can be selected from , , and can be a substituted phenyl (such as , CH 3 . In some embodiments, , a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be where R 1 can be ; R 2 can be –C(=O)R 5 , wherein R 5 can be a substituted bicyclic heteroaryl (such as those described herein); R 3 can be a substituted phenyl (such as and R 4 can be –CH 3 .
[0091] Examples of compounds of Formula (I), including pharmaceutically acceptable salts thereof, include:
or a pharmaceutically acceptable salt of any of the foregoing. [0092] Further examples of compounds of Formula (I), including pharmaceutically acceptable salts thereof, include the following:
, or a pharmaceutically acceptable salt of any of the foregoing. [0093] Additional examples of compounds of Formula (I), including pharmaceutically acceptable salts thereof, include the following: or a pharmaceutically acceptable salt of any of the foregoing. [0094] In some embodiments, a compound can be selected from: pharmaceutically acceptable salt of any of the foregoing. [0095] In some embodiments, a compounds of Formula (I), or a pharmaceutically acceptable salt thereof, cannot be selected from rac-(6S)-7-(4-bromo-3-chloro-benzoyl)-2-[4- (cyclopropoxy)phenyl]-6-methyl-3-oxo-N-[(2-pyrazol-1-ylpheny l)methyl]-6,8-dihydro-5H- imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro-benzoyl)-2-[4- (cyclopropoxy)phenyl]-6-methyl-3-oxo-N-[(2-pyrazol-1-ylpheny l)methyl]-6,8-dihydro-5H- imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6S)-7-(4-bromo-3-chloro-benzoyl)-2-[4- (cyclopropoxy)phenyl]-N-[[2-(4-fluoropyrazol-1-yl)phenyl]met hyl]-6-methyl-3-oxo-6,8- dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro-benzoyl)- 2-[4-(cyclopropoxy)phenyl]-N-[[2-(4-fluoropyrazol-1-yl)pheny l]methyl]-6-methyl-3-oxo- 6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxamide, rac-(6R)-7-(4-bromo-3-chloro- benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3-oxo-N-[[2-(1, 2,4-triazol-1- yl)phenyl]methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-ca rboxamide, rac-(6S)-7-(4- bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl- 3-oxo-N-[[2-(1,2,4-triazol- 1-yl)phenyl]methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1- carboxamide, rac-(6R)-7-(4- bromo-3-cyano-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3 -oxo-N-[(2-pyrimidin-2- ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-car boxamide, rac-(6S)-7-(4- bromo-3-cyano-benzoyl)-2-[4-(cyclopropoxy)phenyl]-6-methyl-3 -oxo-N-[(2-pyrimidin-2- ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-car boxamide, rac-(6R)-7-(4- bromo-3-chloro-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylphen yl)-N-[(2-pyrimidin-2- ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-car boxamide, rac-(6S)-7-(4- bromo-3-chloro-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylphen yl)-N-[(2-pyrimidin-2- ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-car boxamide, rac-(6R)-7-(4- bromo-3-cyano-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylpheny l)-N-[(2-pyrimidin-2- ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-car boxamide, and rac-(6S)-7-(4- bromo-3-cyano-benzoyl)-6-methyl-3-oxo-2-(4-pyrazol-1-ylpheny l)-N-[(2-pyrimidin-2- ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-car boxamide. [0096] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, cannot be a compound or a pharmaceutically acceptable salt of a compound provided in U.S. 2020/0361947 A1, which is hereby incorporated by reference. In some embodiments, R 1 cannot be . In other embodiments, R 1 cannot be . In some embodiments, R 3 cannot be . In other embodiments, R 3 cannot be . In some embodiments, R 5 cannot be In other embodime 5 nts, R cannot be In still other embodiments, R 5 cannot In yet still other embodiments, R 5 cannot be . In some embodiments, when R 3 is , then R 5 cannot be , , In some embodiments, when R 3 then R 1 cannot be In some embodiments, when R 3 is then R 5 cannot be In some embodiments, when R 3 is 1 then R cannot be In some embodiments, when R 3 is then R 4 cannot be –CH 3 . In some embodiments, when R 5 is , , , then R 4 cannot be – CH 3 . In some embodiments, when R 1 is then R 4 cannot be –CH 3 . Synthesis [0097] Compounds of Formula (I) along with those described herein may be prepared in various ways. General synthetic routes for preparing compounds of Formula (I) are shown and described herein along with some examples of starting materials used to synthesize compounds described herein. The routes shown and described herein are illustrative only and are not intended, nor are they to be construed, to limit the scope of the claims in any manner whatsoever. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise alternate routes based on the disclosures herein; all such modifications and alternate routes are within the scope of the claims. Scheme 1 [0098] Compounds of Formula (I), along with pharmaceutically acceptable salts thereof, can be prepared from an intermediate of Formula (II) by cleaving the Boc protecting group in acidic condition, for example, by using HCl in a suitable solvent or by using cupper triflate to provide an intermediate of Formula (III). Compounds of Formula (I), and pharmaceutically acceptable salts thereof, can be obtained by methods know in the art. As an example, acyls of Formula (I) can be obtained by coupling Formula (III) with an acyl chloride, such as an acyl chloride of the general formula R 1 –C(=O)–Cl, or by using an acid (such as R 1 -C(=O)-OH) in presence of a suitable coupling agent (for example TCFH in presence of N-methylimidazole), in a suitable solvent, such as acetonitrile. Scheme 2 [0099] Compounds of Formula (I), along with pharmaceutically acceptable salts thereof, wherein R 2 can be –C(=O)R 5 can be prepared from an intermediate of Formula (VI) whose synthesis is shown in Scheme 2. The ester of Formula (IV) can be saponified using lithium hydroxide or another suitable agent (such as sodium hydroxide) in a suitable solvent such a mixture of water in ethanol, to give an intermediate of Formula (V). The coupling of Formula (V) with an amine of general formula can be achieved using a coupling agent, such as EDCI/HOAT, or another suitable coupling agent (such as HATU in presence of DIPEA) in a suitable solvent to provide an intermediate of Formula (VI). The intermediate of Formula (VI) can be treated as depicted in Scheme 1 to give a compound of Formula (I), along with pharmaceutically acceptable salts thereof, where R 2 can be – C(=O)R 5 .
[0100] Compounds of Formula (IV) can be obtained from 2,5-dichloropyrazine as depicted in Scheme 3. 2,5-dichloropyrazine can be reacted with N- (diphenylmethylene)glycine ethyl ester in a suitable solvent in presence of a base (for example, potassium carbonate) to provide a compound of Formula (VII). Deprotection of Formula (VII) can be accomplished under acidic conditions, for example, in presence of HCl to provide a compound of Formula (VIII). Formula (VIII) can be cyclized to a compound of Formula (IX), for example, using triphosgen in a suitable solvent (such as THF), or CDI in presence of a suitable base (such DIEA) in a suitable solvent (such as THF). Introduction of a R 3 substituent to a compound of Formula (IX) to give a compound of Formula (X) can be achieved by methods known to those skilled in the art. For instance, an intermediate of Formula (X) can be obtained from an intermediate of Formula (IX) by using an alkylating agent of general formula R 3 –Halo, where Halo can be chloro, bromo or iodo, in presence of a base (for example, potassium carbonate) in a suitable solvent. Alternatively, an intermediate of Formula (X) can be obtained by a Mitsunobu reaction using an alcohol of general formula R 3 –OH in a suitable solvent. Other compounds of Formula (X) can be prepared from Formula (IX), a boronic acid of general formula R 3 –B(OH) 2 , and a catalyst (such as Cu(OTf) 2 or Cu(AcO) 2 ), in presence of a suitable base. Other compounds of Formula (X) can be prepared from Formula (IX) using a halogenated aryl or heteroaryl R 3 -Halo, where Halo can be iodo, bromo or chloro, in the presence of copper iodide, potassium carbonate and N 1 ,N 2 -dimethylethane-1,2-diamine, in a solvent, such as DMSO, under heating conditions. Other compounds of Formula (X) can be prepared from Formula (IX) using a halogenated aryl or heteroaryl R 3 -Halo, where Halo can be iodo, bromo or chloro, in the presence of a palladium catalyst (for example, Pd 2 dba3) a ligand (such as Xantphos), a base (for example, cesium carbonate) in a suitable solvent (such as dioxane) under heating conditions. Other methods known in the art to functionalize lactams can also be used. [0101] The chloro of Formula (X) can be transformed to an alkyl or cycloalkyl, for example, methyl and cyclopropyl, using 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane and a cyclopropyl boronic acid, respectively, in the presence of a catalyst (for example, Pd(dppf)Cl 2 , K 2 CO 3 in dioxane, or Pd(OAc) 2 and SPhos in toluene/water). The obtained compound of Formula (XI), where R 4 can be methyl or cyclopropyl, can be reduced under known conditions (such as hydrogenation on Pd/C in ethanol or using sodium borohydride in ethanol) to provide a compound a Formula (XII). Protection of a compound of Formula (XII) using a Boc protecting group can be achieved using conditions known in the art, such as Boc 2 O, in presence of TEA, in a suitable solvent (such as DCM), to give a compound a Formula (IV). [0102] A compound of Formula (IV) can be obtained following the route depicted in Scheme 4. A compound of Formula (IX) can be protected using a PMB group, and conditions known in the art. For example, PMB-Cl can be used in presence of a suitable base (such as K 2 CO 3 ) in a suitable solvent (such as DMF) to provide a compound of Formula (Xa). The chloro can be transformed to an alkyl or a cycloalkyl (for example, methyl and cyclopropyl using 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane and cyclopropyl boronic acid, respectively) in the presence of a catalyst (such as Pd(dppf)Cl 2 , K 2 CO 3 in dioxane, or Pd(OAc) 2 and SPhos in toluene/water) to provide a compound of Formula (XIa). A compound of Formula (XIa), where R 4 can be methyl or cyclopropyl, can be deprotected using conditions, such as hot TFA, to give a compound a Formula (XIII). Reduction and protection with a Boc protecting group of a compound a Formula (XIII) can be achieved in one pot under known conditions known to those skilled in the art (such as hydrogenation on Pd/C in ethanol, or using sodium borohydride in ethanol in presence of Boc 2 O) to obtain a compound a Formula (XIV), where R 4 can be methyl or cyclopropyl. A R 3 substituent can be introduced to a compound of Formula (XIII) using the conditions depicted in Scheme 3 for the synthesis of Formula (X). For example, compounds of Formula (IV) can be obtained by reacting a compound of Formula (XIII), a boronic acid of general formula R 3 –B(OH) 2 , and a catalyst (such as Cu(TfO) 2 ), in presence of a suitable base (such as pyridine) and solvent (such as DMF). Other methods known in the art to functionalize lactams can also be used. Pharmaceutical Compositions [0103] Some embodiments described herein relate to a pharmaceutical composition, that can include an effective amount of a compound described herein (e.g., a compound, or a pharmaceutically acceptable salt thereof, as described herein) and a pharmaceutically acceptable carrier, excipient or combination thereof. A pharmaceutical composition described herein is suitable for human and/or veterinary applications. [0104] As used herein, a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues. For example, without limitation, dimethyl sulfoxide (DMSO) is a commonly utilized carrier that facilitates the uptake of many organic compounds into cells or tissues of a subject. [0105] As used herein, a “diluent” refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and/or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation. A common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the composition of human blood. [0106] As used herein, an “excipient” refers to an inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition. A “diluent” is a type of excipient. [0107] Proper formulation is dependent upon the route of administration chosen. Techniques for formulation and administration of the compounds described herein are known to those skilled in the art. Multiple techniques of administering a compound exist in the art including, but not limited to, oral, rectal, topical, aerosol, injection and parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intranasal and intraocular injections. Pharmaceutical compositions will generally be tailored to the specific intended route of administration. [0108] One may also administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into the infected area, often in a depot or sustained release formulation. Furthermore, one may administer the compound in a targeted drug delivery system, for example, in a liposome coated with a tissue-specific antibody. The liposomes may be targeted to and taken up selectively by the organ. [0109] The pharmaceutical compositions disclosed herein may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes. As described herein, compounds used in a pharmaceutical composition may be provided as salts with pharmaceutically compatible counterions. Methods of Use [0110] Some embodiments described herein relate to a method of treating a HBV and/or HDV infection that can include administering to a subject identified as suffering from the HBV and/or HDV infection an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein. Other embodiments described herein relate to using a compound, or a pharmaceutically acceptable salt thereof, as described herein in the manufacture of a medicament for treating a HBV and/or HDV infection. Still other embodiments described herein relate to the use of a compound, or a pharmaceutically acceptable salt thereof, as described herein or a pharmaceutical composition that includes a compound, or a pharmaceutically acceptable salt thereof, as described herein for treating a HBV and/or HDV infection. [0111] Some embodiments disclosed herein relate to a method of treating a HBV and/or HDV infection that can include contacting a cell infected with the HBV and/or HDV with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein. Other embodiments described herein relate to using a compound, or a pharmaceutically acceptable salt thereof, as described herein in the manufacture of a medicament for treating a HBV and/or HDV infection. Still other embodiments described herein relate to the use of a compound, or a pharmaceutically acceptable salt thereof, as described herein described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein for treating a HBV and/or HDV infection. [0112] Some embodiments disclosed herein relate to a method of inhibiting replication of HBV and/or HDV that can include contacting a cell infected with the HBV and/or HDV with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein. Other embodiments described herein relate to using a compound, or a pharmaceutically acceptable salt thereof, as described herein in the manufacture of a medicament for inhibiting replication of HBV and/or HDV. Still other embodiments described herein relate to the use of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, for inhibiting replication of HBV and/or HDV. [0113] In some embodiments, the HBV infection can be an acute HBV infection. In some embodiments, the HBV infection can be a chronic HBV infection. [0114] Some embodiments disclosed herein relate to a method of treating liver cirrhosis that is developed because of a HBV and/or HDV infection that can include administering to a subject suffering from liver cirrhosis and/or contacting a cell infected with the HBV and/or HDV in a subject suffering from liver cirrhosis with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein. Other embodiments described herein relate to using a compound, or a pharmaceutically acceptable salt thereof, as described herein in the manufacture of a medicament for treating liver cirrhosis with an effective amount of the compound, or a pharmaceutically acceptable salt thereof. Still other embodiments described herein relate to the use of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein for treating liver cirrhosis. [0115] Some embodiments disclosed herein relate to a method of treating liver cancer (such as hepatocellular carcinoma) that is developed because of a HBV and/or HDV infection that can include administering to a subject suffering from the liver cancer and/or contacting a cell infected with the HBV and/or HDV in a subject suffering from the liver cancer with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein. Other embodiments described herein relate to using a compound, or a pharmaceutically acceptable salt thereof, as described herein in the manufacture of a medicament for treating liver cancer (such as hepatocellular carcinoma). Still other embodiments described herein relate to the use of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein for treating liver cancer (such as hepatocellular carcinoma). [0116] Some embodiments disclosed herein relate to a method of treating liver failure that is developed because of a HBV and/or HDV infection that can include administering to a subject suffering from liver failure and/or contacting a cell infected with the HBV and/or HDV in a subject suffering from liver failure with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein. Other embodiments described herein relate to using a compound, or a pharmaceutically acceptable salt thereof, as described herein in the manufacture of a medicament for treating liver failure. Still other embodiments described herein relate to the use of a compound, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition that includes an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein for treating liver failure. [0117] Various indicators for determining the effectiveness of a method for treating an HBV and/or HDV infection are also known to those skilled in the art. Examples of suitable indicators include, but are not limited to, a reduction in viral load indicated by reduction in HBV DNA (or load) (e.g., reduction <10 5 copies/mL in serum), HBV surface antigen (HBsAg) and HBV e-antigen (HBeAg), a reduction in plasma viral load, a reduction in viral replication, a reduction in time to seroconversion (virus undetectable in patient serum), an increase in the rate of sustained viral response to therapy, an improvement in hepatic function, and/or a reduction of morbidity or mortality in clinical outcomes. [0118] As used herein, the terms “treat,” “treating,” “treatment,” “therapeutic,” and “therapy” do not necessarily mean total cure or abolition of the disease or condition. Any alleviation of any undesired signs or symptoms of a disease or condition, to any extent can be considered treatment and/or therapy. Furthermore, treatment may include acts that may worsen the subject’s overall feeling of well-being or appearance. [0119] As used herein, a “subject” refers to an animal that is the object of treatment, observation or experiment. “Animal” includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals. “Mammal” includes, without limitation, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, primates, such as monkeys, chimpanzees, and apes, and, in particular, humans. In some embodiments, the subject is human. [0120] The term “effective amount” is used to indicate an amount of an active compound, or pharmaceutical agent, that elicits the biological or medicinal response indicated. For example, an effective amount of compound can be the amount needed to alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. This response may occur in a tissue, system, animal or human and includes alleviation of the signs or symptoms of the disease being treated. Determination of an effective amount is well within the capability of those skilled in the art, in view of the disclosure provided herein. The effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. [0121] In some embodiments, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described herein is an amount that is effective to achieve a sustained virologic response, for example, a sustained viral response 12 month after completion of treatment. [0122] Subjects who are clinically diagnosed with a HBV and/or HDV infection include “naïve” subjects (e.g., subjects not previously treated for HBV and/or HDV) and subjects who have failed prior treatment for HBV and/or HDV (“treatment failure” subjects). Treatment failure subjects include “non-responders” (subjects who did not achieve sufficient reduction in ALT (alanine aminotransferase) levels, for example, subject who failed to achieve more than 1 log10 decrease from base-line within 6 months of starting an anti-HBV and/or anti-HDV therapy) and “relapsers” (subjects who were previously treated for HBV and/or HDV whose ALT levels have increased, for example, ALT > twice the upper normal limit and detectable serum HBV DNA). Further examples of subjects include subjects with a HBV and/or HDV infection who are asymptomatic. [0123] In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, as described herein can be provided to a treatment failure subject suffering from HBV and/or HDV. In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, as described herein can be provided to a non-responder subject suffering from HBV and/or HDV. In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, as described herein can be provided to a relapser subject suffering from HBV and/or HDV. In some embodiments, the subject can have HBeAg positive chronic hepatitis B. In some embodiments, the subject can have HBeAg negative chronic hepatitis B. In some embodiments, the subject can have liver cirrhosis. In some embodiments, the subject can be asymptomatic, for example, the subject can be infected with HBV and/or HDV but does not exhibit any symptoms of the viral infection. In some embodiments, the subject can be immunocompromised. In some embodiments, the subject can be undergoing chemotherapy. [0124] Examples of agents that have been used to treat HBV and/or HDV include immunomodulating agents, and nucleosides/nucleotides. Examples of immunomodulating agents include interferons (such as IFN-α and pegylated interferons that include PEG-IFN-α- 2a); and examples of nucleosides/nucleotides include lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil. However, some of the drawbacks associated with interferon treatment are the adverse side effects, the need for subcutaneous administration and high cost. Potential advantages of a compound of Formula (I), or a pharmaceutically acceptable salt of any of the foregoing, can be less adverse side effects, delay in the onset of an adverse side effect and/or reduction in the severity of an adverse side effect. A drawback with nucleoside/nucleotide treatment can be the development of resistance, including cross-resistance. [0125] Resistance can be a cause for treatment failure. The term “resistance” as used herein refers to a viral strain displaying a delayed, lessened and/or null response to an anti-viral agent. In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, as described herein can be provided to a subject infected with an HBV and/or HDV strain that is resistant to one or more anti-HBV and/or anti-HDV agents. Examples of anti- viral agents wherein resistance can develop include lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil. In some embodiments, development of resistant HBV and/or HDV strains is delayed when a subject is treated with a compound, or a pharmaceutically acceptable salt thereof, as described herein compared to the development of HBV and/or HDV strains resistant to other HBV and/or HDV anti-viral agents, such as those described. Combination Therapies [0126] In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, as described herein can be used in combination with one or more additional agent(s) for treating and/or inhibiting replication HBV and/or HDV. Additional agents include, but are not limited to, an interferon, nucleoside/nucleotide analogs, a sequence specific oligonucleotide (such as anti-sense oligonucleotide and siRNA), nucleic acid polymers (NAPs, such as nucleic acid polymers that reduce HBsAg levels including STOPS™ compounds) an entry inhibitor and/or a small molecule immunomodulator. Examples of additional agents include recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil. Examples of NAPs include, but are not limited to, REP 2139, REP 2165 and those STOPS™ compounds described in U.S. Publication No. 2020/0147124 A1, which is hereby incorporated by reference for the purpose of describing the STOPS™ compounds provided therein. In some embodiments, the additional agent can be 5’mApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsmAps ln(5m)CpsrApsln( 5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m)CpsmA psln(5m)CpsrA psln(5m)CpsmApsln(5m)CpsmApsln(5m)CpsrApsln(5m)CpsmApsln(5m) CpsmApsln(5m)C psrApsln(5m)CpsmApsln(5m)CpsmApsln(5m)C 3’ (SEQ ID NO: 4), wherein mA is 2’-O- methyladenosine, ps is phosphorothioate, ln(5m)C is locked 5-methylcytidine, and rA is ribo- adenosine. [0127] In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, as described herein can be administered with one or more additional agent(s) together in a single pharmaceutical composition. In some embodiments, a compound, or a pharmaceutically acceptable salt thereof, can be administered with one or more additional agent(s) as two or more separate pharmaceutical compositions. Further, the order of administration of a compound, or a pharmaceutically acceptable salt thereof, as described herein with one or more additional agent(s) can vary. EXAMPLES [0128] Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims. Example 1 7-tert-butyl 1-ethyl 2-(4-cyclopropoxyphenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5 - a]pyrazine-1,7-dicarboxylate (Intermediate 1) [0129] To a stirred solution of 2,5-dichloro-pyrazine (30.0 g, 201 mmol, 1.00 eq.) and ethyl 2-[(diphenylmethylidene)amino]acetate (53.8 g, 201 mmol, 1.00 eq.) in N,N- dimethylformamide (300 mL) was added cesium carbonate (65.6 g, 201 mmol, 1.00 eq.) at room temperature (rt). The mixture was stirred overnight at rt, and the reaction was quenched with water (500 mL). The mixture was extracted with ethyl acetate (3 x 200 mL)/ The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 0-20% ethyl acetate in petroleum ether to afford ethyl 2-(5-chloropyrazin-2-yl)-2-[(diphenylmethylidene)amino]aceta te (48.9 g, 64%) as a yellow solid. LCMS (ESI, m/z): 380 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) į ppm 8.75-8.73 (m, 2H), 7.64-7.62 (m, 2H), 7.57-7.55 (m, 3H), 7.48-7.50 (m, 1H), 7.42-7.45 (m, 2H), 7.20-7.22 (m, 2H), 5.31 (s, 1H), 4.11-4.07 (q, J = 6.2 Hz, 2H), 1.12 (t, J = 6.2 Hz, 3H). [0130] To a stirred solution of ethyl 2-(5-chloropyrazin-2-yl)-2- [(diphenylmethylidene) amino]acetate (40.0 g, 105 mmol, 1.00 eq.) in ether (400) was added 1N hydrochloric acid (150 mL, 150 mmol, 1.42 eq.) at rt. The mixture was stirred overnight at rt and then extracted with ether (2 x 20 mL). The combined water layers were concentrated under reduced pressure to afford ethyl 2-amino-2-(5-chloropyrazin-2-yl)acetate hydrochloric acid salt (20.0 g, crude) as a white solid and used directly into next step without further purification. LCMS (ESI, m/z): 216 [M+H-HCl] + . 1 H NMR (300 MHz, DMSO-d 6 ) į ppm 9.33 (s, 3H), 8.93-8.85 (m, 2H), 5.71 (s, 1H), 4.22-4.17 (q, J = 6.2 Hz, 2H), 1.15 (t, J = 6.2 Hz, 3H). [0131] To a stirred solution of ethyl 2-amino-2-(5-chloropyrazin-2-yl)acetate hydrochloric acid salt (19.0 g, 75.4 mmol, 1.00 eq.) in tetrahydrofuran (200 mL) was added N,N-diisopropylethylamine (30.8 g, 238 mmol, 3.16 eq.) and N,N'-carbonyldiimidazole (12.9 g, 79.3 mmol, 1.05 eq.) at 60 °C. The mixture was stirred for 4 h at 60 °C and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 0-5% methanol in dichloromethane to afford ethyl 6-chloro-3- oxo-2H-imidazo[1,5-a]pyrazine-1-carboxylate (11.0 g, 60%) as a yellow solid. LCMS (ESI, m/z): 242 [M+H] + . 1 H NMR (300 MHz, DMSO-d 6 ) į ppm 12.49 (s, 1H), 8.82 (s, 1H), 7.95 (s, 1H), 4.33-4.27 (q, J = 6.2 Hz, 2H), 1.31 (t, J = 6.2 Hz, 3H). [0132] A 250 mL of round bottom flask was charged with ethyl 6-chloro-3-oxo- 2H-imidazo[1,5-a]pyrazine-1-carboxylate (3.00 g, 12.4 mmol, 1.00 eq.), 4- cyclopropoxyphenylboronic acid (2.65 g, 14.9 mmol, 1.20 eq.), pyridine (2.94 g, 37.1 mmol, 2.99 eq.), copper(II) trifluoromethanesulfonate (4.49 g, 12.4 mmol, 1.00 eq.) and N,N- dimethylformamide (100 mL). The mixture was stirred for 2 h at 60 °C under oxygen atmosphere. The mixture was added ethyl acetate (100 mL) and washed with water (3 x 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 0-50% ethyl acetate in petroleum ether to afford ethyl 6-chloro- 2-(4-cyclopropoxyphenyl)-3-oxoimidazo[1,5-a]pyrazine-1-carbo xylate (3.40 g, 73%) as a yellow solid. LCMS (ESI, m/z): 374 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 9.08 (d, J = 1.6 Hz, 1H), 7.75 (d, J = 1.6 Hz, 1H), 7.30-7.20 (m, 2H), 7.17-7.11 (m, 2H), 4.25 (q, J = 7.1 Hz, 2H), 3.76 (tt, J = 4.8, 3.8 Hz, 1H), 2.95 (s, 1H), 2.88 (s, 1H), 1.24 (t, J = 7.1 Hz, 3H), 0.80 (s, 2H). [0133] A 250 mL of round bottom flask was charged with ethyl 6-chloro-2-(4- cyclopropoxyphenyl)-3-oxoimidazo[1,5-a]pyrazine-1-carboxylat e (3.40 g, 9.10 mmol, 1.00 eq.), [1'1-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.700 g, 0.957 mmol, 0.11 eq.), potassium carbonate (3.77 g, 27.3 mmol, 3.00 eq.) and 1,4-dioxane (100 mL). Trimethyl-1,3,5,2,4,6-trioxatriborinane (4.57 g, 18.2 mmol, 2.00 eq., 50% in THF) was then added at rt under nitrogen atmosphere. The mixture was stirred overnight at 110 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 0-50% ethyl acetate in petroleum ether to afford ethyl 2-(4-cyclopropoxyphenyl)-6-methyl-3-oxoimidazo[1,5-a]pyrazin e-1- carboxylate (2.20 g, 68%) as a yellow solid. LCMS (ESI, m/z): 354 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 9.23 (d, J = 1.6 Hz, 1H), 7.52 (t, J = 1.5 Hz, 1H), 7.30-7.24 (m, 2H), 7.19- 7.13 (m, 2H), 4.27 (q, J = 7.1 Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H), 3.85-3.72 (m, 1H), 2.41 (s, 3H), 1.27 (td, J = 7.2, 2.4 Hz, 3H), 0.82 (d, J = 4.5 Hz, 2H). [0134] A 250 mL of round bottom flask was charged with ethyl 2-(4- cyclopropoxyphenyl)-6-methyl-3-oxoimidazo[1,5-a]pyrazine-1-c arboxylate (2.20 g, 6.23 mmol, 1.00 eq.) and methanol (100 mL). Sodium borohydride (1.18 g, 31.2 mmol, 5.01 eq.) was added at 0 °C. The mixture was stirred for 2 h at rt. The reaction was quenched with water (10 mL). To the mixture was added sodium bicarbonate (2.62 g, 31.1 mmol, 5.00 eq.) and di-tert-butyl dicarbonate (6.79 g, 31.1 mmol, 5.00 eq.) at rt. The mixture was stirred overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 0-50% ethyl acetate in petroleum ether to afford 7-tert-butyl 1-ethyl 2-(4-cyclopropoxyphenyl)-6- methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarboxyla te (2.00 g, 70%) as a yellow solid. LCMS (ESI, m/z): 458 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 7.21-7.16 (m, 2H), 7.10-7.04 (m, 2H), 5.31-5.20 (m, 1H), 4.82 (dd, J = 13.6, 1.7 Hz, 1H), 4.33 (d, J = 19.4 Hz, 1H), 4.21-4.08 (m, 2H), 3.85 (dd, J = 12.7, 1.4 Hz, 1H), 3.76-3.70 (m, 1H), 3.63 (dd, J = 12.8, 4.7 Hz, 1H), 1.51 (s, 9H), 1.26 (d, J = 6.9 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H), 0.87-0.84 (m, 2H), 0.78 (d, J = 4.5 Hz, 2H). Example 2 (6S*)-7-tert-butyl 1-ethyl 2-(4-cyclopropoxyphenyl)-6-methyl-3-oxo-5H,6H,8H- imidazo[1,5-a]pyrazine-1,7-dicarboxylate (intermediate 1a) and (6R*)-7-tert-butyl 1-ethyl 2- (4-cyclopropoxyphenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a ]pyrazine-1,7- dicarboxylate (Intermediate 1b) [0135] Intermediate 1 was dissolved in ethanol and then was separated into its two enantiomers intermediate 1a (first eluting enantiomer) and intermediate 1b (second eluting enantiomer) by SFC, using a column Lux A2 (21.2 mm x 250 mm, 5um), at 40 °C, with a flow rate of 50 mL/min and 100 bar, under isochratic conditions (30:70 EtOH:CO 2 (0.2% v/v NH 3 ). Example 3 7-(tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-methyl-3- oxo-2,3,5,6,7,8- hexahydroimidazo[1,5-a]pyrazine-1-carboxylic acid (Intermediate 2) [0136] A solution of NaOH (4 eq., 357 mg, 8.92 mmol) in H 2 O (1.5 mL) was added to a solution of Intermediate 1 (1 eq., 1020 mg, 2.23 mmol) in EtOH (15 mL). The mixture was stirred at rt for 3 h. The mixture was concentrated to remove ethanol. Water (15 mL) was added, and the aqueous layer was extracted with Et 2 O (2x 20 mL). The aqueous layer was acidified with HCl 1 N to pH 2 and extracted with DCM (3x 30 mL). The combined organic layers were dried with magnesium sulfate, filtered and evaporated to dryness to afford 7-(tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-methyl-3- oxo- 2,3,5,6,7,8-hexahydroimidazo[1,5-a]pyrazine-1-carboxylic acid (Intermediate 2) (830 mg, 78%). Example 4 (6S*)-7-(tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-met hyl-3-oxo-2,3,5,6,7,8- hexahydroimidazo[1,5-a]pyrazine-1-carboxylic acid (Intermediate 2a) and (6R*)-7-(tert- butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-methyl-3-oxo-2,3, 5,6,7,8- hexahydroimidazo[1,5-a]pyrazine-1-carboxylic acid (Intermediate 2b) [0137] Intermediates 2a and 2b were synthetized according to the procedures for the synthesis of 7-(tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-methyl-3- oxo- 2,3,5,6,7,8-hexahydroimidazo[1,5-a]pyrazine-1-carboxylic acid (Intermediate 2), starting from Intermediate 1a and Intermediate 1b, respectively. Example 5 (6R*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-6 -methyl-N-(2-(5-methyl- 1,3,4-oxadiazol-2-yl)benzyl)-3-oxo-2,3,5,6,7,8-hexahydroimid azo[1,5-a]pyrazine-1- carboxamide (1b) Methyl 2-(((tert-butoxycarbonyl)amino)methyl)benzoate [0138] A solution of Boc 2 O (1.1 eq., 2.29 g, 10.47 mmol) in anhydrous DCM (12.8 mL) was added to a solution of methyl 2-(aminomethyl)benzoate hydrochloride (1 eq., 1.92 g, 9.52 mmol), Et 3 N (2.5 eq., 3.31 mL, 23.8 mmol) and DMAP (0.1 eq., 0.12 g, 0.95 mmol) in anhydrous DCM (38.4 mL). The mixture was stirred at rt for 1 h. Sat. NH 4 Cl (50 mL) was added, and the aqueous layer was extracted with AcOEt (3 x 50 mL). The combined organic layers were washed with HCl 1M (40 mL), brine (30 mL), dried with magnesium sulfate, filtered and evaporated to dryness. The crude product was purified by filtration on a short pad of silica gel using 30% of AcOEt in CyH to provide methyl 2-(((tert- butoxycarbonyl)amino)methyl)benzoate (2.26 g, 89%) as a colorless oil. LCMS (ESI, m/z): 166.1 [M-Boc+H] + . Tert-butyl (2-(hydrazinecarbonyl)benzyl)carbamate [0139] Hydrazine monohydrate (10 eq., 4.13 mL, 85.2 mmol) was added to a solution of methyl 2-(((tert-butoxycarbonyl)amino)methyl)benzoate (1 eq., 2.26 g, 8.52 mmol) in MeOH (58.3 mL) under N 2 . The mixture was heated at 65 °C for 24 h. The mixture was then evaporated to dryness to afford tert-butyl (2- (hydrazinecarbonyl)benzyl)carbamate (3.78 g, quant.) as a white solid, which was used as such. LCMS (ESI, m/z): 210.1 [M-tBu +H] + . Tert-butyl (2-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl)carbamate [0140] PTSA.H 2 O (0.1 eq., 0.18 g, 0.94 mmol) was added to a suspension of tert- butyl (2-(hydrazinecarbonyl)benzyl)carbamate (1 eq., 2.49 g, 9.38 mmol) in trimethyl orthoacetate (16.7 eq., 20 mL, 156 mmol) under N 2 . The mixture was heated at 100 °C for 1 h. Sat. NaHCO 3 (10 mL) was added, and the aqueous layer was extracted with AcOEt (3 x 10 mL). The combined organic layers were washed with brine (30 mL), dried with magnesium sulfate, filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (from 0% to 50% of AcOEt in CyH) to give tert-butyl (2- (5-methyl-1,3,4-oxadiazol-2-yl)benzyl)carbamate (1.76 g, 65%) as a white solid. LCMS (ESI, m/z): 290.1 [M+H] + . 1 H-NMR (CDCl 3 , 300 MHz, 25 °C) δ ppm 1.40 (s, 9H), 2.64 (s, 3H), 4.58 (d, J = 6.6 Hz, 2H), 6.14 (br s, 1H), 7.39-7.44 (m, 1H), 7.46-7.51 (m, 1H), 7.63 (d, J = 7.2 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H). (2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)methanamine hydrochloride [0141] A solution of tert-butyl (2-(5-methyl-1,3,4-oxadiazol-2- yl)benzyl)carbamate (1 eq., 400 mg, 1.38 mmol) in HCl 4N in dioxane (20 eq., 6.91 mL, 27.65 mmol) was stirred under N 2 at rt for 1 h. The mixture was evaporated to dryness to afford (2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)methanamine hydrochloride (328 mg, quant.) as a white solid. LCMS (ESI, m/z): 190.1 [M+H] + . 1 H-NMR (DMSO-d6, 300 MHz, 25 °C) į ppm 2.62 (s, 3H), 4.46 (q, J = 2.4 Hz, 2H), 7.61-7.77 (m, 3H), 7.99 (d, J = 6.9 Hz, 1H), 8.46 (br s, 3H). Tert-butyl (R*)-2-(4-cyclopropoxyphenyl)-6-methyl-1-((2-(5-methyl-1,3,4 -oxadiazol-2- yl)benzyl)carbamoyl)-3-oxo-2,5,6,8-tetrahydroimidazo[1,5-a]p yrazine-7(3H)- carboxylate [0142] HATU (1.2 eq., 106.2 mg, 0.28 mmol), (2-(5-methyl-1,3,4-oxadiazol-2- yl)phenyl)methanamine hydrochloride (1.1 eq., 57.8 mg, 0.26 mmol) and DIPEA (5 eq., 0.19 mL, 1.16 mmol) were added to a suspension of Intermediate 2b (1 eq., 100 mg, 0.23 mmol) in anhydrous DCM (4 mL) under N 2 . The mixture was stirred at rt for 30 min. Sat. Na 2 CO 3 (15 mL) was added to the mixture, and the aqueous phase was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with water (4 x 15 mL) and brine (15 mL), dried over MgSO4, filtered and evaporated to dryness to afford the title compound (134 mg, 96%) as a brown solid, which was used without further purification. LCMS (ESI, m/z): 601.2 [M+H] + . (R*)-2-(4-cyclopropoxyphenyl)-6-methyl-N-(2-(5-methyl-1,3,4- oxadiazol-2-yl)benzyl)-3- oxo-2,3,5,6,7,8-hexahydroimidazo[1,5-a]pyrazine-1-carboxamid e hydrochloride [0143] A solution of tert-butyl (R*)-2-(4-cyclopropoxyphenyl)-6-methyl-1-((2-(5- methyl-1,3,4-oxadiazol-2-yl)benzyl)carbamoyl)-3-oxo-2,5,6,8- tetrahydroimidazo[1,5- a]pyrazine-7(3H)-carboxylate (1 eq., 134 mg, 0.22 mmol) in HCl 4N in dioxane (20 eq., 1.12 mL, 4.46 mmol) was stirred under N 2 at rt for 1 h. The mixture was evaporated to dryness to afford the title compound (125 mg, quant.) as a red solid, which was used as such. LCMS (ESI, m/z): 501.1 [M+H] + . (R*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-6- methyl-N-(2-(5-methyl- 1,3,4-oxadiazol-2-yl)benzyl)-3-oxo-2,3,5,6,7,8-hexahydroimid azo[1,5-a]pyrazine-1- carboxamide (1b) [0144] TCFH (1.2 eq., 89.6 mg, 0.32 mmol) and N-methylimidazole (5 eq., 0.106 mL, 1.33 mmol) were added to a suspension of (R*)-2-(4-cyclopropoxyphenyl)-6-methyl-N- (2-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl)-3-oxo-2,3,5,6,7,8- hexahydroimidazo[1,5- a]pyrazine-1-carboxamide hydrochloride (0.84 eq., 120 mg, 0.22 mmol) and 4-bromo-3- chlorobenzoic acid (1.1 eq., 69.0 mg, 0.29 mmol) in anhydrous MeCN (2.55 mL) under N 2 . The mixture was stirred at rt for 1 h. Sat. Na 2 CO 3 (10 mL) was added to the mixture, and the aqueous phase was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with water (3 x 15 mL), brine (20 mL), dried over MgSO 4 , filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (from 0% to 10% of MeOH in DCM). The resulting solid was triturated in Et 2 O to give the title compound (1b) (86 mg, 54%) as a white solid. LCMS (ESI, m/z): 716.9/718.9/720.9 [M+H] + . 1 H-NMR (DMSO-d6, 600 MHz, 80 °C) į ppm 0.63-0.73 (m, 2H), 0.77-0.87 (m, 2H), 1.27 (d, J = 6.9 Hz, 3H), 2.58 (s, 3H), 3.64-3.71 (m, 2H), 3.83 (hept., J = 3.0 Hz, 1H), 4.50 (d, J = 18.3 Hz, 1H), 4.54-4.77 (m, 3H), 5.06-5.32 (m, 1H), 6.95-7.00 (m, 2H), 7.12- 7.20 (m, 3H), 7.31 (d, J = 7.1 Hz, 1H), 7.37 (dd, J = 8.1, 1.7 Hz, 1H), 7.45-7.51 (m, 2H), 7.73 (d, J = 1.7 Hz, 1H), 7.85 (d, J = 7.9 Hz, 2H). Example 6 (S*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-6- methyl-N-(2-(5-methyl- 1,3,4-oxadiazol-2-yl)benzyl)-3-oxo-2,3,5,6,7,8-hexahydroimid azo[1,5-a]pyrazine-1- carboxamide (1a) [0145] (S*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-6- methyl- N-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl)-3-oxo-2,3,5,6,7, 8-hexahydroimidazo[1,5- a]pyrazine-1-carboxamide (1a) was synthetized following the procedure as depicted for (1b), using Intermediate 2a in step 5 in place of Intermediate 2b. LCMS (ESI, m/z): 716.9/718.9/720.9 [M+H] + . 1 H-NMR (DMSO-d6, 600 MHz, 80 °C) į ppm 0.63-0.73 (m, 2H), 0.77-0.87 (m, 2H), 1.27 (d, J = 6.9 Hz, 3H), 2.58 (s, 3H), 3.64-3.71 (m, 2H), 3.83 (hept., J = 3.0 Hz, 1H), 4.50 (d, J = 18.3 Hz, 1H), 4.54-4.77 (m, 3H), 5.06-5.32 (m, 1H), 6.95-7.00 (m, 2H), 7.12-7.20 (m, 3H), 7.31 (d, J = 7.1 Hz, 1H), 7.37 (dd, J = 8.1, 1.7 Hz, 1H), 7.45- 7.51 (m, 2H), 7.73 (d, J = 1.7 Hz, 1H), 7.85 (d, J = 7.9 Hz, 2H). Example 7 (R*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-N- (2-fluoro-6-(pyrimidin-4- yl)benzyl)-6-methyl-3-oxo-2,3,5,6,7,8-hexahydroimidazo[1,5-a ]pyrazine-1-carboxamide (2b) Tert-butyl (2-bromo-6-fluorobenzyl)carbamate [0146] A solution of Boc 2 O (1.2 eq., 1.28 g, 5.88 mmol) in anhydrous DCM (5 mL) was added at 0 °C to a solution of Et 3 N (1.2 eq., 0.82 mL, 5.88 mmol) and 2-bromo-6- fluorobenzylamine (1 eq., 1.0 g, 4.90 mmol) in anhydrous DCM (15 mL) under N 2 . The mixture was stirred at rt for 1 h and evaporated to dryness. Water (50 mL) and HCl 1M (10 mL) were added. The aqueous solution was extracted with AcOEt (3 x 20 mL). The combined organic layers were and washed with HCl 1M (20 mL), brine (20 mL), dried over MgSO 4 , filtered and evaporated to dryness to give tert-butyl (2-bromo-6- fluorobenzyl)carbamate (1.39 g, 93%) as a yellow oil, which was used without further purification. LCMS (ESI, m/z): 247.9/249.9 [M-tBu +H] + . 1 H-NMR (DMSO-d6, 400 MHz, 25 °C) į ppm 1.37 (s, 9H), 4.26 (d, J = 4.0 Hz, 2H), 7.14 (br s, 1H), 7.20-7.31 (m, 2H), 7.45 (d, J = 8.0 Hz, 1H). Tert-butyl (2-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ben zyl)carbamate [0147] A mixture of tert-butyl (2-bromo-6-fluorobenzyl)carbamate (1 eq., 1.1 g, 3.62 mmol), potassium acetate (2.5 eq., 0.89 g, 9.04 mmol), bis(pinacolato)diboron (1.2 eq., 1.10 g, 4.34 mmol) and Pd(dppf)Cl 2 •DCM (0.1 eq., 0.3 g, 0.36 mmol) in anhydrous dioxane (11 mL) under N 2 was heated to 80 °C for 4 h. After cooling to rt, water (50 mL) was added. The solution was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO 4 , filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (from 0% to 30% AcOEt in CyH) to give tert-butyl (2-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzyl)carbamate (852 mg, 67%) as a colorless oil. LCMS (ESI, m/z): 252.1 [M-Boc +H] + . Tert-butyl (2-fluoro-6-(pyrimidin-4-yl)benzyl)carbamate [0148] A mixture of tert-butyl (2-fluoro-6-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)carbamate (1 eq., 883 mg, 2.52 mmol), 4-chloropyrimidine hydrochloride (1 eq., 380 mg, 2.52 mmol), sodium carbonate 2.4 M in water (5 eq., 5 mL, 12.6 mmol) and Pd(dppf)Cl 2 •DCM (0.05 eq., 102.7 mg, 0.13 mmol) in dioxane (11 mL) was heated at 100 °C for 1 h. After cooling to rt, the mixture was diluted with water and extracted with AcOEt (3 x 70 mL). The combined organic layers were washed with brine, dried over MgSO 4 , filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (from 0% to 65% AcOEt in CyH) to give tert-butyl (2- fluoro-6-(pyrimidin-4-yl)benzyl)carbamate (657 mg, 86%) as a colorless oil. LCMS (ESI, m/z): 304.1 [M+H] + . 1 H-NMR (DMSO-d6, 300 MHz, 25 °C) į ppm 1.29 (s, 9H), 4.31 (d, J = 4.5 Hz, 2H), 6.91 (br s, 1H), 7.31-7.39 (m, 2H), 7.45-7.52 (m, 1H), 7.73 (d, J = 5.1 Hz, 1H), 8.90 (d, J = 5.1 Hz, 1H), 9.26 (s, 1H). (2-fluoro-6-(pyrimidin-4-yl)phenyl)methanamine • TFA [0149] TFA (20 eq., 1.62 mL, 21.8 mmol) was added to a solution of tert-butyl (2-fluoro-6-(pyrimidin-4-yl)benzyl)carbamate (1 eq., 330 mg, 1.09 mmol) in DCM (7 mL) under N 2 . The mixture was stirred at rt for 1 h. The mixture was evaporated to dryness and the residue was triturated in Et 2 O to give (2-fluoro-6-(pyrimidin-4- yl)phenyl)methanamine•TFA (227 mg, 66%) as a black solid. LCMS (ESI, m/z): 204.1 [M+H] + . Tert-butyl (R*)-2-(4-cyclopropoxyphenyl)-1-((2-fluoro-6-(pyrimidin-4- yl)benzyl)carbamoyl)-6-methyl-3-oxo-2,5,6,8-tetrahydroimidaz o[1,5-a]pyrazine-7(3H)- carboxylate [0150] A solution of Intermediate 2b (1 eq., 108.3 mg, 0.25 mmol), (2-fluoro-6- (pyrimidin-4-yl)phenyl)methanamine•TFA (1.1 eq., 88 mg, 0.28 mmol), HATU (1.2 eq., 115 mg, 0.303 mmol) and DIPEA (10 eq., 0.42 mL, 2.52 mmol) in anhydrous DCM (3.8 mL) was stirred at rt under N 2 for 1 h. Sat. Na 2 CO 3 (20 mL) was added to the mixture, and the aqueous phase was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with water (3 x 15 mL), brine (30 mL), dried over MgSO 4 , filtered and evaporated to dryness. The crude product was purified by flash chromatography on silica gel (from 0% to 10% MeOH in DCM) to give the title product (117 mg, 76%) as a red oil. LCMS (ESI, m/z): 615.1 [M+H] + . (R*)-2-(4-cyclopropoxyphenyl)-N-(2-fluoro-6-(pyrimidin-4-yl) benzyl)-6-methyl-3-oxo- 2,3,5,6,7,8-hexahydroimidazo[1,5-a]pyrazine-1-carboxamide hydrochloride [0151] A solution of tert-butyl (R*)-2-(4-cyclopropoxyphenyl)-1-((2-fluoro-6- (pyrimidin-4-yl)benzyl)carbamoyl)-6-methyl-3-oxo-2,5,6,8-tet rahydroimidazo[1,5- a]pyrazine-7(3H)-carboxylate (1 eq., 129 mg, 0.21 mmol) in HCl 4N in dioxane (20 eq., 1.05 mL, 4.2 mmol) was stirred at rt under N 2 for 1 h. The mixture was evaporated to dryness to afford the title compound (129 mg, quant.) as a dark red sticky solid, which was used as such. LCMS (ESI, m/z): 515.1 [M+H] + . (R*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-N- (2-fluoro-6-(pyrimidin- 4-yl)benzyl)-6-methyl-3-oxo-2,3,5,6,7,8-hexahydroimidazo[1,5 -a]pyrazine-1- carboxamide (2b) [0152] TCFH (1.2 eq., 35.69 mg, 0.13 mmol) and N-methylimidazole (5 eq., 0.042 mL, 0.53 mmol) were added to a suspension of (R*)-2-(4-cyclopropoxyphenyl)-N-(2- fluoro-6-(pyrimidin-4-yl)benzyl)-6-methyl-3-oxo-2,3,5,6,7,8- hexahydroimidazo[1,5- a]pyrazine-1-carboxamide hydrochloride (1 eq., 61 mg, 0.11 mmol) and 4-bromo-3- chlorobenzoic acid (1.1 eq., 27.45 mg, 0.12 mmol) in anhydrous MeCN (0.5 mL) under N 2 . The mixture was stirred at rt for 2 h. Sat. Na 2 CO 3 (10 mL) was added to the mixture, and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (3 x 10 mL), brine (30 mL), dried over MgSO 4 , filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (from 0% to 10% MeOH in DCM). The resulting solid was purified by reverse phase flash chromatography (from 0% to 100% MeCN in water + 0.1% TFA). The tubes containing the product were combined and MeCN was evaporated. The resulting aqueous solution was neutralized with sat. NaHCO 3 and extracted with EtOAc (4 x 10 mL). The combined organic layers were washed with water (20 mL), dried over MgSO 4 , filtered and evaporated to dryness to give (2b) (31 mg, 36 mg) as a tan solid. LCMS (ESI, m/z): 728.9/730.9/732.9 [M+H] + . 1 H-NMR (DMSO-d6, 600 MHz, 80 °C) į ppm 0.52-0.59 (m, 2H), 0.71-0.77 (m, 2H), 1.26 (d, J = 6.6 Hz, 3H), 3.66 (d, J = 2.9 Hz, 2H), 3.72 (hept, J = 3.0 Hz, 1H), 4.32-4.42 (m, 2H), 4.47 (d, J = 18.3 Hz, 1H), 4.59 (br. s, 1H), 5.08-5.21 (m, 1H), 6.86 (br. s, 1H), 6.90 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 7.31 (t, J = 9.0 Hz, 1H), 7.35-7.37 (m, 2H), 7.48-7.54 (m, 1H), 7.65 (d, J = 5.1 Hz, 1H), 7.72 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 8.86 (d, J = 5.2 Hz, 1H), 9.11 (s, 1H). Example 8 (S*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-N- (2-fluoro-6-(pyrimidin-4- yl)benzyl)-6-methyl-3-oxo-2,3,5,6,7,8-hexahydroimidazo[1,5-a ]pyrazine-1-carboxamide (2a) [0153] (S*)-7-(4-bromo-3-chlorobenzoyl)-2-(4-cyclopropoxyphenyl)-N- (2- fluoro-6-(pyrimidin-4-yl)benzyl)-6-methyl-3-oxo-2,3,5,6,7,8- hexahydroimidazo[1,5- a]pyrazine-1-carboxamide (2a) was synthetized following the procedure as depicted for (2b), using Intermediate 2a in step 5, in place of Intermediate 2b. LCMS (ESI, m/z): 728.9/730.9/732.9 [M+H] + . 1 H-NMR (DMSO-d6, 600 MHz, 80 °C) į ppm 0.52-0.59 (m, 2H), 0.71-0.77 (m, 2H), 1.26 (d, J = 6.6 Hz, 3H), 3.66 (d, J = 2.9 Hz, 2H), 3.72 (hept, J = 3.0 Hz, 1H), 4.32-4.42 (m, 2H), 4.47 (d, J = 18.3 Hz, 1H), 4.59 (br. s, 1H), 5.08-5.21 (m, 1H), 6.86 (br. s, 1H), 6.90 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 7.31 (t, J = 9.0 Hz, 1H), 7.35-7.37 (m, 2H), 7.48-7.54 (m, 1H), 7.65 (d, J = 5.1 Hz, 1H), 7.72 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 8.86 (d, J = 5.2 Hz, 1H), 9.11 (s, 1H). Example 9 (6S*)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl ]-6-methyl-3-oxo-N-[(2- pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]py razine-1-carboxamide (ϯĂ) and (6R*)-7-(4-bromo-3-chloro-benzoyl)-2-[4-(cyclopropoxy)phenyl ]-6-methyl-3-oxo-N- [(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5- a]pyrazine-1-carboxamide (3b) [0154] Compounds (3a) and (3b) were synthetized following the pathway described to synthetize (2b), using Intermediate 2 in place of Intermediate 2b, and (2- (pyrimidin-2-yl)phenyl)methanamine in place of (2-fluoro-6-(pyrimidin-4- yl)phenyl)methanamine in step 5. The resulting racemic compound (3) was then further separated into its two enantiomers (3a) (first eluting enantiomer) and (3b) (second eluting enantiomer) by SFC, using a column Lux C3 (20mm x 250mm, 5um) at 40 °C, with a flow rate of 50 mL/min and 100 bar, under isochratic conditions (35:65 EtOH:CO 2 (0.1% v/v NH 3 ). LCMS (ESI, m/z): 713/715/717 [M+H] + . 1 H-NMR (DMSO, 600 MHz, 80 °C) į ppm 0.57-0.61 (m, 2H), 0.73-0.79 (m, 2H), 1.28 (d, J = 6.5 Hz, 3H), 3.64-3.69 (m, 2H), 3.70-3.75 (m, 1H), 4.47-4.55 (m, 3H), 4.56-4.69 (m, 1H), 5.12-5.29 (m, 1H), 6.91 (d, J = 8.8 Hz, 2H), 7.09-7.18 (m, 3H), 7.26-7.30 (m, 1H), 7.38 (dd, J = 8.2 Hz, 1.8 Hz, 1H), 7.39-7.45 (m, 3H), 7.73 (d, J = 1.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.95-7.99 (m, 1H), 8.81 (d, J = 4.6 Hz, 2H). Example 10 (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{4-[(2R)-2-hy droxypropoxy]phenyl}-6- methyl-3-oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H,8H-i midazo[1,5-a]pyrazine-1- carboxamide (55a) and (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl) phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (55b) Tert-butyl (2-(pyrimidin-4-yl)benzyl)carbamate [0155] A 100 mL round bottom flask was charged with 2-{[(tert- butoxycarbonyl)amino]methyl}phenylboronic acid (5.00 g, 19.9 mmol, 1.00 eq.), 4- chloropyrimidine (2.96 g, 25.9 mmol, 1.30 eq.), K 2 CO 3 (8.26 g, 59.7 mmol, 3.00 eq.), Pd(PPh 3 ) 4 (0.920 g, 0.797 mmol, 0.04 eq.) and 1,4-dioxane (100 mL). The solution was stirred overnight at 100 °C under a nitrogen atmosphere and then concentrated under reduced pressure. The reaction was quenched with water (200 mL), and the mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:5) to afford tert-butyl N-{[2-(pyrimidin-4- yl)phenyl]methyl}carbamate (5.00 g, 88% yield) as a white solid. LCMS (ESI, m/z): 286 [M+H] +. 1-[2-(pyrimidin-4-yl)phenyl]methanamine hydrochloride [0156] A 100 mL round-bottom flask was charged with tert-butyl N-{[2- (pyrimidin-4-yl)phenyl]methyl}carbamate (1.50 g, 5.26 mmol, 1.00 eq.) and hydrogen chloride (20 mL, 4M in 1,4-dioxane). The mixture was stirred for 2 h at rt and then concentrated under reduced pressure to afford 1-[2-(pyrimidin-4-yl)phenyl]methanamine hydrochloride (0.85 g, crude) as an off-white solid. LCMS (ESI, m/z): 186 [M+H-HCl] + . 7-tert-butyl 1-ethyl 2-{4-[(tert-butyldimethylsilyl)oxy]phenyl}-6-methyl-3-oxo-5H ,6H, 8H-imidazo[1,5-a]pyrazine-1,7-dicarboxylate) [0157] A 100 mL round-bottom flask was charged with 7-tert-butyl 1-ethyl 6- methyl-3-oxo-2H,5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarbox ylate (3.00 g, 9.22 mmol, 1.00 eq.), 4-[(tert-butyldimethylsilyl)oxy] phenylboronic acid (2.56 g, 10.1 mmol, 1.10 eq.), Cu(OTf) 2 (3.33 g, 9.22 mmol, 1.00 eq.), pyridine (2.19 g, 27.660 mmol, 3.00 eq.) and DMF (30 mL). The mixture was stirred for 3 h at 60 °C under an O 2 atmosphere and then diluted with ethyl acetate (300 mL). The mixture was washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:2) to afford to afford 7-tert-butyl 1-ethyl 2-{4-[(tert- butyldimethylsilyl) oxy]phenyl}-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-1 ,7- dicarboxylate (4.20 g, 87% yield) as a yellow oil. LCMS (ESI, m/z): 532 [M+H] + . 7-(tert-butoxycarbonyl)-2-(4-hydroxyphenyl)-6-methyl-3-oxo-5 H,6H,8H-imidazo[1,5- a]pyrazine-1-carboxylic acid [0158] A 100 mL round-bottom flask was charged with 7-tert-butyl 1-ethyl 2-{4- [(tert-butyldimethylsilyl)oxy]phenyl}-6-methyl-3-oxo-5H,6H,8 H-imidazo[1,5-a]pyrazine- 1,7-dicarboxylate (4.26 g, 8.01 mmol, 1.00 eq.), NaOH (0.640 g, 16.0 mmol, 2.00 eq.), EtOH (40 mL) and water (10 mL). The mixture was stirred for 3 h at 60 °C and then concentrated under reduced pressure. The mixture was diluted with water (50 mL) and the pH value of the mixture was adjusted to about 6 with 1 mol/L HCl (aq.). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 7-(tert-butoxycarbonyl)-2-(4-hydroxyphenyl)-6-methyl-3-oxo-5 H,6H,8H- imidazo[1,5-a]pyrazine-1-carboxylic acid (2.20 g, 71% yield) as a red solid. LCMS (ESI, m/z): 390 [M+H] + . tert-butyl 2-(4-hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyrimidin-4-yl)ph enyl]methyl} carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate [0159] A 250 mL round-bottom flask was charged with 7-(tert-butoxycarbonyl)- 2-(4-hydroxyphenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]py razine-1-carboxylic acid (500 mg, 1.28 mmol, 1.00 eq.), 1-[2-(pyrimidin-4-yl)phenyl]methanamine hydrochloride (342 mg, 1.54 mmol, 1.20 eq.), DIEA (829 mg, 6.42 mmol, 5.00 eq.), HOBT (208 mg, 1.54 mmol, 1.20 eq.), EDCI (295 mg, 1.54 mmol, 1.20 eq.) and DMF (10 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (9:1) to afford tert-butyl 2-(4-hydroxyphenyl)-6-methyl-3-oxo-1-({[2- (pyrimidin-4-yl)phenyl]methyl}carbamyl)-5H,6H,8H-imidazo[1,5 -a]pyrazine-7-carboxylate (650 mg, 91% yield) as purple oil. LCMS (ESI, m/z): 557 [M+H] + . 2-{4-[(2R)-2-hydroxypropoxy]phenyl}-6-methyl-3-oxo-1-({[2-(p yrimidin-4-yl)phenyl] methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxyl ate [0160] A 250 mL round-bottom flask was charged with tert-butyl 2-(4- hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyrimidin-4-yl)phenyl] methyl}carbamoyl)- 5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate (350 mg, 0.629 mmol, 1.00 eq.), (R)- propylene oxide (2 mL), K 2 CO 3 (260 mg, 1.88 mmol, 3.00 eq.) and CH 3 CN (10 mL). The mixture was stirred overnight at 80 °C and then concentrated under reduced pressure. The residue was diluted with water (30 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with CH 2 Cl 2 :MeOH (9:1) to afford tert-butyl 2-{4-[(2R)-2-hydroxypropoxy]phenyl}-6-methyl-3-oxo-1-({[2-(p yrimidin- 4-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazin e-7-carboxylate (200 mg, 52% yield) as a yellow oil. LCMS (ESI, m/z): 615 [M+H] + . 2-{4-[(2R)-2-hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(py rimidin-4-yl)phenyl] methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoracetic acid salt [0161] A 100 mL round-bottom flask was charged with tert-butyl 2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-1-({[2-(pyrimidin-4- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (200 mg, 0.325 mmol, 1.00 eq.), TFA (2 mL) and DCM (10 mL). The mixture was stirred for 2 h at rt and then concentrated under reduced pressure to afford 2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl) phenyl]methyl}- 5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoracetic acid salt (205 mg, crude) as a yellow oil. LCMS (ESI, m/z): 515 [M-TFA+H] + .
(6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{4-[(2R)-2 -hydroxypropoxy]phenyl}-6- methyl-3-oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H,8H-i midazo[1,5-a]pyrazine- 1-carboxamide (55a) and (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl) phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (55b) [0162] A 100 mL round bottom flask was charged with 2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl) phenyl]methyl}- 5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (205 mg, 0.326 mmol, 1.00 eq.), 4-bromo-3-(trifluoromethyl)benzoic acid (105 mg, 0.391 mmol, 1.20 eq.), EDCI (75.1 mg, 0.391 mmol, 1.20 eq.), HOBT (52.9 mg, 0.391 mmol, 1.20 eq.), DIEA (210 mg, 1.630 mmol, 5.00 eq.) and DMF (10 mL). The mixture was stirred overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with CH2Cl2:MeOH (10:1) to afford the crude product. The crude product was purified by prep-CHIRAL-HPLC with the following conditions: Column: Column: CHIRALPAK IE, 2 x 25 cm, 5 ^m; Mobile Phase A: MtBE (0.5% 2M NH 3 - MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 14 mL/min; Gradient: 20% B to 20% B in 30 min; Wave Length: 220/254 nm to afford the final products. [0163] (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl) phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (55a) (the first eluting diastereoisomer, 31.7 mg, 13% yield) as a white solid. LCMS (ESI, m/z): 765 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.77-8.74 (m, 2H), 7.82 (d, J = 4.0 Hz, 2H), 7.54-7.41 (m, 6H), 7.15 (d, J = 4.0 Hz, 2H), 6.84-6.81 (m, 1H), 6.64 (d, J = 4.0 Hz, 2H), 5.23 (s, 1H), 4.65 (d, J = 8.0 Hz, 1H), 4.45- 4.32 (m, 2H), 4.09-3.84 (m, 2H), 3.74-3.69 (m, 2H), 3.58-3.54 (m, 1H), 2.50 (s, 1H), 1.65 (s, 1H), 1.41 (d, J = 4.0 Hz, 3H), 1.26 (d, J = 2.0 Hz, 3H). [0164] (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{4-[(2R)-2- hydroxypropoxy]phenyl}-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl) phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (55b) (the second eluting diastereoisomer, 39.7 mg, 16% yield) as a white solid. LCMS (ESI, m/z): 765 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.77-8.74 (m, 2H), 7.82 (d, J = 4.0 Hz, 2H), 7.54-7.41 (m, 6H), 7.15 (d, J = 4.0 Hz, 2H), 6.84-6.81 (m, 1H), 6.64 (d, J = 4.0 Hz, 2H), 5.23 (s, 1H), 4.65 (d, J = 8.0 Hz, 1H), 4.45- 4.32 (m, 2H), 4.09-3.84 (m, 2H), 3.74-3.69 (m, 2H), 3.58-3.54 (m, 1H), 1.41 (d, J = 4.0 Hz, 3H), 1.26 (d, J = 2.0 Hz, 3H). Example 11 (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-3-oxo- N-{[2-(pyrimidin-2- yl)phenyl]methyl}-2-{4-[(2R)-3,3,3-trifluoro-2-hydroxypropox y]phenyl}-5H,6H,8H- imidazo[1,5-a]pyrazine-1-carboxamide (71a) and (6S*)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-3-oxo-N-{[2-(pyrimidin-2- yl)phenyl]methyl}-2-{4- [(2R)-3,3,3-trifluoro-2-hydroxypropoxy]phenyl}-5H,6H,8H-imid azo[1,5-a]pyrazine-1- carboxamide (71b) tert-butyl N-{[2-(pyrimidin-2-yl)phenyl]methyl}carbamate [0165] A 100 mL round bottom flask was charged with 2-{[(tert-butoxycarbonyl) amino] methyl}phenylboronic acid (3.00 g, 11.9 mmol, 1.00 eq.), 2-chloro-pyrimidine (1.64 g, 14.3 mmol, 1.20 eq.), K2CO3 (4.95 g, 35.8 mmol, 3.00 eq.), Pd(PPh3)4 (0.690 g, 0.597 mmol, 0.05 eq.) and 1,4-dioxane (20 mL). The solution was stirred overnight at 100 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:5) to afford tert-butyl N-{[2-(pyrimidin-2-yl)phenyl] methyl}carbamate (2.50 g, 73% yield) as a white solid. LCMS (ESI, m/z): 286 [M+H] + . 1-[2-(pyrimidin-2-yl)phenyl]methanamine hydrochloride [0166] A 100 mL round-bottom flask was charged with tert-butyl N-{[2- (pyrimidin-2-yl)phenyl]methyl}carbamate (1.00 g, 3.51 mmol, 1.00 eq.) and hydrogen chloride (20 mL, 4M in 1,4-dioxane). The solution was stirred for 2 h at rt and then concentrated under reduced pressure to afford 1-[2-(pyrimidin-2-yl)phenyl]methanamine hydrochloride (0.770 g, crude) as a white solid. LCMS (ESI, m/z): 186 [M+H-HCl] + . tert-butyl 2-(4-hydroxyphenyl)-6-methyl-3-oxo-1-((2-(pyrimidin-2- yl)benzyl)carbamoyl)-2,5,6,8-tetrahydroimidazo[1,5-a]pyrazin e-7(3H)-carboxylate [0167] A 100 mL round-bottom flask was charged with 7-(tert-butoxycarbonyl)- 2-(4-hydroxyphenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]py razine-1-carboxylic acid (500 mg, 1.28 mmol, 1.00 eq.), 1-[2-(pyrimidin-2-yl)phenyl]methanamine hydrochloride (285 mg, 1.284 mmol, 1.00 eq.), EDCI (320 mg, 1.67 mmol, 1.03 eq.), HOBT (226 mg, 1.67 mmol, 1.30 eq.), DIEA (830 mg, 6.42 mmol, 5.00 eq.) and DMF (8 mL). The mixture was stirred for overnight at rt and then diluted with ethyl acetate (150 mL). The mixture was washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (9:1) to afford tert-butyl 2-(4-hydroxyphenyl)- 6-methyl-3-oxo-1-({[2-(pyrimidin-2-yl)phenyl]methyl}carbamoy l)-5H,6H,8H-imidazo[1,5- a]pyrazine-7-carboxylate (550 mg, 77% yield) as a yellow solid. LCMS (ESI, m/z): 557 [M+H] + . tert-butyl 6-methyl-3-oxo-1-((2-(pyrimidin-2-yl)benzyl)carbamoyl)-2-(4- ((R)-3,3,3- trifluoro-2-hydroxypropoxy)phenyl)-2,5,6,8-tetrahydroimidazo [1,5-a]pyrazine-7(3H)- carboxylate [0168] A 250 mL round-bottom flask was charged with tert-butyl 2-(4- hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyrimidin-4-yl)phenyl] methyl}carbamoyl)- 5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate (280 mg, 0.503 mmol, 1.00 eq.), (2R)-2- (trifluoromethyl)oxirane (84.6 mg, 0.754 mmol, 1.50 eq.), K 2 CO 3 (208 mg, 1.51 mmol, 3.00 eq.) and CH 3 CN (10 mL). The mixture was stirred for overnight at 80 °C and then concentrated under reduced pressure. The residue was diluted with water (30 mL). The aqueous layer was extracted with ethyl acetate (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep- TLC with CH 2 Cl 2 :MeOH (9:1) to afford tert-butyl 6-methyl-3-oxo-1-((2-(pyrimidin-2- yl)benzyl)carbamoyl)-2-(4-((R)-3,3,3-trifluoro-2-hydroxyprop oxy)phenyl)-2,5,6,8- tetrahydroimidazo[1,5-a]pyrazine-7(3H)-carboxylate (230 mg, 68% yield) as a yellow solid. LCMS (ESI, m/z): 669 [M+H] + . 6-methyl-3-oxo-N-(2-(pyrimidin-2-yl)benzyl)-2-(4-((R)-3,3,3- trifluoro-2- hydroxypropoxy)phenyl)-2,3,5,6,7,8-hexahydroimidazo[1,5-a]py razine-1-carboxamide trifluoroacetic acid salt [0169] A 100 mL round-bottom flask was charged with tert-butyl 6-methyl-3- oxo-1-((2-(pyrimidin-2-yl)benzyl)carbamoyl)-2-(4-((R)-3,3,3- trifluoro-2- hydroxypropoxy)phenyl)-2,5,6,8-tetrahydroimidazo[1,5-a]pyraz ine-7(3H)-carboxylate (230 mg, 0.325 mmol, 1.00 eq.), TFA (2 mL)and DCM (10 mL) at rt. The mixture was stirred for 2 h at rt under air atmosphere and then concentrated under reduced pressure to afford 6- methyl-3-oxo-N-(2-(pyrimidin-2-yl)benzyl)-2-(4-((R)-3,3,3-tr ifluoro-2- hydroxypropoxy)phenyl)-2,3,5,6,7,8-hexahydroimidazo[1,5-a]py razine-1-carboxamide trifluoroacetic acid salt (250 mg, crude) as a yellow oil. LCMS (ESI, m/z): 569 [M- TFA+H] + . (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-3-oxo- N-{[2-(pyrimidin-2- yl)phenyl]methyl}-2-{4-[(2R)-3,3,3-trifluoro-2-hydroxypropox y]phenyl}-5H,6H,8H- imidazo[1,5-a]pyrazine-1-carboxamide (71a) and (6S*)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-3-oxo-N-{[2-(pyrimidin-2- yl)phenyl]methyl}-2-{4- [(2R)-3,3,3-trifluoro-2-hydroxypropoxy]phenyl}-5H,6H,8H-imid azo[1,5-a]pyrazine-1- carboxamide (71b) [0170] A 100 mL round-bottom flask was charged with 6-methyl-3-oxo-N-(2- (pyrimidin-2-yl)benzyl)-2-(4-((R)-3,3,3-trifluoro-2-hydroxyp ropoxy)phenyl)-2,3,5,6,7,8- hexahydroimidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (205 mg, 0.300 mmol, 1.00 eq.), 4-bromo-3-(trifluoromethyl)benzoic acid (96.9 mg, 0.360 mmol, 1.20 eq.), EDCI (69.0 mg, 0.360 mmol, 1.20 eq.), HOBT (48.7 mg, 0.360 mmol, 1.20 eq.), DIEA (194 mg, 1.500 mmol, 5.00 eq.) and DMF (5 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with CH 2 Cl 2 :MeOH (10:1) to afford the crude product. The crude product was purified by prep-CHIRAL-HPLC with the following conditions: Column: Chiral ART Cellulose-SA, 2 x 25 cm, 5 ^m; Mobile Phase A: MtBE (0.5% 2M NH 3 -MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL/min; Gradient: 13% B to 13% B in 18 min; Wave Length: 254/220 nm to afford the final products. [0171] (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-3-oxo- N-{[2- (pyrimidin-2-yl)phenyl]methyl}-2-{4-[(2R)-3,3,3-trifluoro-2- hydroxypropoxy]phenyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (71a) (the first eluting diastereoisomer, 16.7 mg, 6.8% yield ) as a white solid. LCMS (ESI, m/z): 819 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.59 (d, J = 4.0 Hz, 2H), 8.16-8.12 (m, 1H), 7.84-7.82 (m, 2H), 7.52-7.43 (m, 4H), 7.18-7.16 (m, 1H), 7.05 (d, J = 4.0 Hz, 2H), 6.84 (s, 1H), 6.47 (d, J = 4.0 Hz, 2H), 5.34 (s, 2H), 4.68-4.56 (m, 2H), 4.48-4.46 (m, 1H) 4.26-4.18 (m, 1H), 3.94-3.90 (m, 1H), 3.85-3.81 (m, 2H), 3.71 (d, J = 6.0 Hz, 1H), 3.45 (s, 1H), 1.41 (d, J = 2.0 Hz, 3H). [0172] (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-3-oxo- N-{[2- (pyrimidin-2-yl)phenyl]methyl}-2-{4-[(2R)-3,3,3-trifluoro-2- hydroxypropoxy]phenyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (71b) (the second eluting diastereoisomer, 22.3 mg, 9.1% yield ). LCMS (ESI, m/z): 819 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.59 (d, J = 4.0 Hz, 2H), 8.16-8.12 (m, 1H), 7.84-7.82 (m, 2H), 7.52-7.43 (m, 4H), 7.18-7.16 (m, 1H), 7.05 (d, J = 4.0 Hz, 2H), 6.84 (s, 1H), 6.47 (d, J = 4.0 Hz, 2H), 5.34 (s, 2H), 4.68-4.56 (m, 2H), 4.48-4.46 (m, 1H) 4.26-4.18 (m, 1H), 3.94-3.90 (m, 1H), 3.85-3.81 (m, 2H), 3.71 (d, J = 6.0 Hz, 1H), 3.45 (s, 1H), 1.41 (d, J = 2.0 Hz, 3H). Example 12 (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-2-(4-{ 6-methyl-2,6- diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (73a) and (6S*)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-2-(4-{6-methyl-2,6-diazas piro[3.3]heptan-2-yl}phenyl)- 3-oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H,8H-imidazo[ 1,5-a]pyrazine-1- carboxamide (73b) 7-tert-butyl 1-ethyl 2-(4-iodophenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]pyraz ine- 1,7-dicarboxylate [0173] A 40 ml vial was charged with 7-tert-butyl 1-ethyl 6-methyl-3-oxo- 2H,5H,6H,8H-imidazo [1,5-a]pyrazine-1,7-dicarboxylate (500 mg, 1.54 mmol, 1.00 eq.), 4- iodophenylboronic acid (457 mg, 1.84 mmol, 1.20 eq.), pyridine (267 mg, 3.38 mmol, 2.20 eq.), Cu(OTf) 2 (111 mg, 0.307 mmol, 0.200 eq.) and DMF (20 mL). The mixture was stirred overnight at 60 °C under an O 2 atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:3) to afford 7-tert-butyl 1-ethyl 2-(4-iodophenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]pyraz ine-1,7-dicarboxylate (730 mg, 90% yield) as an off-white solid. LCMS (ESI, m/z): 528 [M+H] + . tert-butyl 1-(benzylcarbamoyl)-2-(4-{6-methyl-2,6-diazaspiro[3.3]heptan -2-yl}phenyl) - 3-oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate [0174] A 250 mL round-bottom flask was charged with 7-tert-butyl 1-ethyl 2-(4- iodophenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-1 ,7-dicarboxylate (900 mg, 1.71 mmol, 1.00 eq.), 2-methyl -2,6-diazaspiro[3.3]heptane dihydrochloride (631 mg, 3.41 mmol, 2.00 eq.), Pd(OAc)2 (38.3 mg, 0.171 mmol, 0.10 eq.), XPhos (163 mg, 0.341 mmol, 0.20 eq.), Cs 2 CO 3 (3.34 g, 10.2 mmol, 6.00 eq.) and toluene (20 mL) The mixture was stirred for overnight at 90 °C under a nitrogen atmosphere. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (10:1) to afford tert-butyl 1- (benzylcarbamoyl)-2-(4-{6-methyl-2,6-diazaspiro[3.3]heptan-2 -yl}phenyl)-3-oxo- 5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate (660 mg, 69% yield) as a light yellow solid. LCMS (ESI, m/z): 512 [M+H] + . 1-(ethoxycarbonyl)-6-methyl-2-(4-{6-methyl-2,6-diazaspiro[3. 3]heptan-2-yl}phenyl)-3- oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylic acid [0175] A 40 mL vial was charged with 7-tert-butyl 1-ethyl 6-methyl-2-(4-{6- methyl-2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-5H,6H,8H -imidazo[1,5-a]pyrazine- 1,7-dicarboxylate (650 mg, 1.27 mmol, 1.00 eq.), MeOH (16 mL), NaOH (102 mg, 2.55 mmol, 2.00 eq.) and water (4 mL) at rt. The mixture was stirred 3 h at 60 °C. The reaction was quenched with water (20 mL). The mixture was adjusted to pH 7 with HCl (1 mol/L aq.). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 1-(ethoxycarbonyl)-6-methyl-2-(4-{6-methyl- 2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-5H,6H,8H-imidaz o[1,5-a]pyrazine-7- carboxylic acid (770 mg, crude) as an off-white solid. LCMS (ESI, m/z): 484 [M+H] + .
tert-butyl 6-methyl-2-(4-{6-methyl-2,6-diazaspiro[3.3]heptan-2-yl}pheny l)-3-oxo-1-({[2- (pyrimidin-4-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1, 5-a]pyrazine-7- carboxylate [0176] A 40 mL vial was charged with 7-(tert-butoxycarbonyl)-6-methyl-2-(4-{6- methyl-2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-5H,6H,8H -imidazo[1,5-a]pyrazine-1- carboxylic acid (200 mg, 0.414 mmol, 1.00 eq.), 1-[2-(pyrimidin-4-yl)phenyl]methanamine hydrochloride (110 mg, 0.497 mmol, 1.20 eq.), DIEA (267 mg, 2.07 mmol, 5.00 eq.), HOBT (83.8 mg, 0.621 mmol, 1.50 eq.), EDCI (119 mg, 0.621 mmol, 1.50 eq.) and DMF (20 mL). The mixture was stirred overnight at rt. The reaction was quenched with water (20 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (10:1) to afford tert-butyl 6-methyl-2-(4-{6- methyl-2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-1-({[2-( pyrimidin-4- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (110 mg, 41% yield) as a yellow solid. LCMS (ESI, m/z): 651 [M+H] + . 6-methyl-2-(4-{6-methyl-2,6-diazaspiro[3.3]heptan-2-yl}pheny l)-3-oxo-N-{[2-(pyrimidin -4-yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-ca rboxamide trifluoroacetic acid salt [0177] A 100 mL round-bottom flask was charged with tert-butyl 6-methyl-2-(4- {6-methyl-2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-1-({[ 2-(pyrimidin-4- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (110 mg, 0.169 mmol, 1.00 eq.), TFA (4 mL) and DCM (20 mL). The mixture was stirred for 2 h at rt and then concentrated under reduced pressure to afford 6-methyl-2-(4-{6-methyl-2,6- diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (118 mg, crude) as a light yellow oil. LCMS (ESI, m/z): 550 [M+H-TFA] + . (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-2-(4-{ 6-methyl-2,6- diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (73a) and (6S*)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-2-(4-{6-methyl-2,6-diazas piro[3.3]heptan-2- yl}phenyl)-3-oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H, 8H-imidazo[1,5- a]pyrazine-1-carboxamide (73b) [0178] A 40 mL vial was charged with 6-methyl-2-(4-{6-methyl-2,6- diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (118 mg, 0.177 mmol, 1.00 eq.), 4-bromo-3-(trifluoromethyl)benzoic acid (57.2 mg, 0.212 mmol, 1.20 eq.), EDCI (51.0 mg, 0.265 mmol, 1.50 eq.), DIEA (68.7 mg, 0.531 mmol, 3.00 eq.), HOBT (35.9 mg, 0.265 mmol, 1.50 eq.) and DMF (5 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (20 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (8:1) to afford the crude product. The crude product was purified by purified by prep-CHIRAL- HPLC with the following conditions: Column: CHIRALPAK IE, 2 x 25 cm, 5 ^m; Mobile Phase A: MtBE (0.5% 2M NH 3 -MeOH)—HPLC, Mobile Phase B: MeOH—HPLC; Flow rate: 20 mL/min; Gradient: 50% B to 50% B in 18 min; Wave Length: 254/220 nm to afford the final products. [0179] (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-2-(4-{ 6-methyl- 2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-N-{[2-(pyrimidi n-4-yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (73a) (the first elution, 17.3 mg, 12% yield) as a white solid. LCMS (ESI, m/z): 801 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 8.83 (d, J = 1.4 Hz, 1H), 8.75 (d, J = 5.2 Hz, 1H), 7.83 (d, J = 8.2 Hz, 2H), 7.58-7.39 (m, 6H), 7.09-6.99 (m, 2H), 6.77 (t, J = 6.2 Hz, 1H), 6.22-6.12 (m, 2H), 5.35 (s, 2H), 4.66 (d, J = 18.9 Hz, 1H), 4.38 (qd, J = 13.8, 6.2 Hz, 2H), 3.87 (d, J = 12.7 Hz, 1H), 3.74 (s, 5H), 3.40 (s, 4H), 2.37 (s, 3H), 1.41 (d, J = 6.9 Hz, 3H). [0180] (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-6-methyl-2-(4-{ 6-methyl- 2,6-diazaspiro[3.3]heptan-2-yl}phenyl)-3-oxo-N-{[2-(pyrimidi n-4-yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (73b) (17.2 mg, 12% yield) as a white solid. LCMS (ESI, m/z): 801 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 8.83 (d, J = 1.4 Hz, 1H), 8.75 (d, J = 5.3 Hz, 1H), 7.83 (d, J = 8.1 Hz, 2H), 7.56-7.39 (m, 6H), 7.10-7.00 (m, 2H), 6.77 (t, J = 6.2 Hz, 1H), 6.17 (d, J = 8.6 Hz, 2H), 5.32 (s, 1H), 4.66 (d, J = 18.9 Hz, 1H), 4.38 (qd, J = 13.8, 6.2 Hz, 2H), 3.87 (d, J = 12.8 Hz, 1H), 3.75 (s, 5H), 3.43 (s, 4H), 2.38 (s, 3H), 1.42 (d, J = 6.9 Hz, 3H).
Example 13 7-(4-bromo-3-(trifluoromethyl)benzoyl)-6-methyl-3-oxo-N-(2-( pyridazin-3-yl)benzyl)-2-(4- (3,3,3-trifluoro-2-hydroxy-2-methylpropoxy)phenyl)-2,3,5,6,7 ,8-hexahydroimidazo[1,5- a]pyrazine-1-carboxamide (85) and separation into its 4 diastereoisomers (85a), (85b), (85c) and (85d) tert-butyl (2-(pyridazin-3-yl)benzyl)carbamate [0181] A 250 mL round-bottom flask was charged with 2-{[(tert- butoxycarbonyl)amino]methyl}phenylboronic acid (2.00 g, 7.96 mmol, 1.00 eq.), 3- chloropyridazine (1.37 g, 11.9 mmol, 1.50 eq.), K 2 CO 3 (3.30 g, 23.9 mmol, 3.00 eq.), Pd(PPh 3 ) 4 (0.460 g, 0.398 mmol, 0.05 eq.), H 2 O (2 mL) and 1,4-dioxane (20 mL). The mixture was stirred for 2 h at 100 °C under a nitrogen atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with dichloromethane (3 x 100 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate to afford tert-butyl N- {[2-(pyridazin-3-yl)phenyl]methyl}carbamate (2.10 g, 92% yield) as an off-white solid. LCMS (ESI, m/z):286 [M+H] + . (2-(pyridazin-3-yl)phenyl)methanamine hydrochloride [0182] A mixture of tert-butyl N-{[2-(pyridazin-3-yl)phenyl]methyl}carbamate (2.00 g, 7.02 mmol, 1.00 eq.) and HCl (gas) (50 mL, 4M in dioxane) was stirred for 2 h at rt and then concentrated under reduced pressure to afford (2-(pyridazin-3- yl)phenyl)methanamine hydrochloride (1.55, crude) as an off-white solid. LCMS (ESI, m/z): 186 [M+H-HCl] + . tert-butyl 2-(4-hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyridazin-3- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate [0183] A 100 mL round-bottom flask was charged with 7-(tert-butoxycarbonyl)- 2-(4-hydroxyphenyl)-6-methyl-3-oxo-5H,6H,8H-imidazo[1,5-a]py razine-1-carboxylic acid (0.800 g, 2.05 mmol, 1.00 eq.), (2-(pyridazin-3-yl)phenyl)methanamine hydrochloride (0.455 g, 2.05 mmol, 1.00 eq.), EDCI (0.512 g, 2.67 mmol, 1.30 eq.), HOBT (0.361 g, 2.67 mmol, 1.30 eq.), DIEA (1.33 g, 10.3 mmol, 5.00 eq.) and DMF (20 mL). The mixture was stirred for overnight at rt under a nitrogen atmosphere and then diluted with ethyl acetate (200 mL). The mixture was washed with water (3 x 100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH:CH 2 Cl 2 (1:10) to afford tert-butyl 2-(4-hydroxyphenyl)- 6-methyl-3-oxo-1-({[2-(pyridazin-3-yl)phenyl]methyl}carbamoy l)-5H,6H,8H-imidazo[1,5- a]pyrazine-7-carboxylate (400 mg, 35% yield) as a yellow solid. LCMS (ESI, m/z): 557 [M+H] + . 118 tert-butyl 6-methyl-3-oxo-1-({[2-(pyridazin-3-yl)phenyl]methyl}carbamoy l)-2-[4-(3,3,3- trifluoro-2-hydroxy-2-methylpropoxy)phenyl]-5H,6H,8H-imidazo [1,5-a]pyrazine-7- carboxylate [0184] A 100 mL round-bottom flask was charged with tert-butyl 2-(4- hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyridazin-3-yl)phenyl] methyl}carbamoyl)- 5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate (400 mg, 0.719 mmol, 1.00 eq.), 2-methyl- 2-(trifluoromethyl)oxirane (109 mg, 0.863 mmol, 1.20 eq.), K 2 CO 3 (199 mg, 1.44 mmol, 2.00 eq.) and CH 3 CN (10 mL). The mixture was stirred for overnight at 80 °C under a nitrogen atmosphere. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with ethyl acetate to afford tert- butyl 6-methyl-3-oxo-1-({[2-(pyridazin-3-yl)phenyl]methyl}carbamoy l)-2-[4-(3,3,3- trifluoro-2-hydroxy-2-methylpropoxy)phenyl]-5H,6H,8H-imidazo [1,5-a]pyrazine-7- carboxylate (305 mg, 62% yield) as a brown solid. LCMS (ESI, m/z): 683 [M+H] + . 6-methyl-3-oxo-N-{[2-(pyridazin-3-yl)phenyl]methyl}-2-[4-(3, 3,3-trifluoro-2-hydroxy-2- methylpropoxy)phenyl]-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-c arboxamide trifluoroacetic acid salt [0185] A 100 mL vial was charged with tert-butyl 6-methyl-3-oxo-1-({[2- (pyridazin-3-yl)phenyl]methyl}carbamoyl)-2-[4-(3,3,3-trifluo ro-2-hydroxy-2- methylpropoxy)phenyl]-5H,6H,8H-imidazo[1,5-a]pyrazine-7-carb oxylate (305 mg, 0.447 mmol, 1.00 eq.), TFA (1 mL) and DCM (5 mL). The mixture was stirred for 2 h at rt and then concentrated under reduced pressure to afford 6-methyl-3-oxo-N-{[2-(pyridazin-3- yl)phenyl]methyl}-2-[4-(3,3,3-trifluoro-2-hydroxy-2-methylpr opoxy)phenyl]-5H,6H,7H,8H- imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (315 mg, crude) as a brown oil. LCMS (ESI, m/z): 583 [M+H-TFA] + . 7-(4-bromo-3-(trifluoromethyl)benzoyl)-6-methyl-3-oxo-N-(2-( pyridazin-3-yl)benzyl)-2- (4-(3,3,3-trifluoro-2-hydroxy-2-methylpropoxy)phenyl)-2,3,5, 6,7,8- hexahydroimidazo[1,5-a]pyrazine-1-carboxamide (85) and separation into its 4 diastereoisomers (85a), (85b), (85c) and (85d) [0186] A 100 mL round-bottom flask was charged with 6-methyl-3-oxo-N-{[2- (pyridazin-3-yl)phenyl]methyl}-2-[4-(3,3,3-trifluoro-2-hydro xy-2-methylpropoxy)phenyl]- 5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (311 mg, 0.446 mmol, 1.00 eq.), 4-bromo-3-(trifluoromethyl)benzoic acid (156 mg, 0.580 mmol, 1.30 eq.), EDCI (1110 mg, 0.580 mmol, 1.30 eq.), HOBT (78.4 mg, 0.580 mmol, 1.30 eq.), DIEA (2880 mg, 2.23 mmol, 5.00 eq.) and DMF (8 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with CH 2 Cl 2 :MeOH (10:1) to afford the crude product. 120 The crude product was purified by prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IF, 2 x 25 cm, 5 μm; Mobile Phase A: MtBE(0.5% 2M NH 3 -MeOH)- -HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL/min; Gradient: 20% B to 20% B in 16 min; Wave Length: 220/254 nm to afford the product (85-1) (the first elution) and (85- 2) (the second elution). The product (85-1) was purified by Prep-Chiral-HPLC with the following conditions Column: CHIRALPAK IG, 2 x 25 cm, 5 μm; Mobile Phase A: Hex: DCM=3: 1(0.5% 2M NH 3 -MeOH), Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 15% B to 15% B in 21 min; Wave Length: 220/254 nm to afford the final products [0187] (85a) (the first elution, 13.0 mg, 3.5% yield) as a white solid. LCMS (ESI, m/z): 833 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 9.09 (d, J = 4.8 Hz, 1H), 7.90-7.70 (m, 2H), 7.65-7.30 (m, 7H), 7.20-7.05 (m, 2H), 6.85 (d, J = 5.1 Hz 1H), 6.53 (d, J = 8.7 Hz 2H), 5.11 (s, 1H), 4.66 (d, J = 18.6 Hz, 1H), 4.45-4.20 (m, 2H), 4.00-3.80 (m, 2H), 3.75-3.60 (m, 2H), 3.60-3.30 (m, 1H), 1.41 (d, J =4.5 Hz, 6H). [0188] (85b) (the second elution, 13.0 mg, 3.5% yield) as a white solid. LCMS (ESI, m/z): 833 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 9.15-8.90 (m, 1H), 7.90-7.70 (m, 2H), 7.65-7.30 (m, 7H), 7.20-7.05 (m, 2H), 6.85 (d, J = 5.1 Hz 1H), 6.53 (d, J = 8.7 Hz, 2H), 5.11 (s, 2H), 4.66 (d, J = 18.6 Hz 1H), 4.45-4.20 (m, 2H), 4.00-3.80 (m, 2H), 3.75-3.60 (m, 2H), 3.50-3.35 (m, 1H), 1.41 (d, J =5.4 Hz, 6H). [0189] The product (85-2) was purified by prep-Chiral-HPLC with the following conditions Column: Lux 5um Cellulose-2, 2.12*25 cm, 5 ^m; Mobile Phase A: Hex(0.5% 2M NH3-MeOH)--HPLC, Mobile Phase B: MeOH: EtOH=1: 1--HPLC; Flow rate: 20 mL/min; Gradient: 40% B to 40% B in 54 min; Wave Length: 220/254 nm to afford the final products. [0190] (85c) (the first elution, 9 mg) as a white solid. LCMS (ESI, m/z): 833 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 9.15-8.90 (m, 1H), 7.90-7.70 (m, 2H), 7.65-7.30 (m, 7H), 7.20-7.05 (m, 2H), 6.85 (d, J = 5.1 Hz 1H), 6.53 (d, J = 8.7 Hz 2H), 5.11 (s, 2H), 4.66 (d, J = 18.6 Hz 1H), 4.45-4.20 (m, 2H), 4.00-3.80 (m, 2H), 3.75-3.60 (m, 2H), 3.50-3.20 (m, 1H), 1.41 (d, J =4.5 Hz, 6H). [0191] (85d) (the second elution, 10.5) as a white solid. LCMS (ESI, m/z): 833 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 9.15-8.90 (m, 1H), 7.90-7.70 (m, 2H), 7.65-7.30 (m, 7H), 7.20-7.05 (m, 2H), 6.85 (d, J = 5.1 Hz 1H), 6.53 (d, J = 8.7 Hz 2H), 5.11 (s, 2H), 4.66 (d, J = 18.6 Hz 1H), 4.45-4.20 (m, 2H), 4.00-3.80 (m, 2H), 3.75-3.15 (m, 3H), 1.41 (d, J =3.6 Hz, 6H). Example 14 (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{1-[(2R)-2-hy droxypropyl]indazol-5-yl}-6- methyl-3-oxo-N-{[2-(pyrimidin-2-yl)phenyl]methyl}-5H,6H,8H-i midazo [1,5-a]pyrazine-1- carboxamide (91a) and (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{1-[(2R)-2- hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-N-{[2-(pyrimidin- 2-yl)phenyl]methyl}- 5H,6H,8H-imidazo [1,5-a]pyrazine-1-carboxamide (91b) [0192] A 100 mL round-bottom flask was charged with the 5-bromo-1H-indazole (500 mg, 2.54 mmol, 1.00 eq.), (R)-2-methyloxirane (177 mg, 3.05 mmol, 1.20 eq.), Cs 2 CO 3 (2.48 g, 7.61 mmol, 3.00 eq.) and DMF (10 mL). The mixture was stirred for overnight at 90 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford (R)-1-(5-bromo-1H-indazol-1-yl)propan-2-ol (450 mg, 69% yield) as a light yellow solid. LCMS (ESI, m/z): 255 [M+H] + . (R)-1-(5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1H-indazol-1 -yl)propan-2-ol [0193] A 250 mL round-bottom flask was charged with (R)-1-(5-bromo-1H- indazol-1-yl)propan-2-ol (500 mg, 1.960 mmol, 1.00 eq.), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (885 mg, 3.92 mmol, 2.00 eq.), KOAc (577 mg, 5.88 mmol, 3.00 eq.), Pd(PPh 3 ) 2 Cl 2 (137 mg, 0.196 mmol, 0.10 eq.) and DMSO (10 mL). The mixture was stirred for overnight at 60 °C under a nitrogen atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford (R)-1-(5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1H-indazol-1 -yl)propan-2-ol (570 mg, crude) as a yellow oil. LCMS (ESI, m/z): 289 [M+H] + . 7-(tert-butyl) 1-ethyl 2-(1-((R)-2-hydroxypropyl)-1H-indazol-5-yl)-6-methyl-3-oxo- 2,5,6,8-tetrahydroimidazo[1,5-a]pyrazine-1,7(3H)-dicarboxyla te [0194] A 100 mL round-bottom flask was charged with (R)-1-(5-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)-1H-indazol-1-yl)propan-2-ol (0.570 g, 2.59 mmol, 1.00 eq.), 7-tert- butyl 1-ethyl 6-methyl-3-oxo-2H,5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarb oxylate (1.01 g, 3.11 mmol, 1.20 eq.), Cu(OTf) 2 (0.940 g, 2.59 mmol, 1.00 eq.), pyridine (0.610 g, 7.77 mmol, 3.00 eq.) and DMF (10 mL). The mixture was stirred for overnight at 60 °C under an oxygen atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (10:1) to afford 7-(tert-butyl) 1-ethyl 2-(1-((R)-2-hydroxypropyl)-1H- indazol-5-yl)-6-methyl-3-oxo-2,5,6,8-tetrahydroimidazo[1,5-a ]pyrazine-1,7(3H)- dicarboxylate (400 mg, 31% yield) as a light yellow solid. LCMS (ESI, m/z):500 [M+H] + . 7-(tert-butoxycarbonyl)-2-{1-[(2S)-2-hydroxypropyl]indazol-5 -yl}-6-methyl-3-oxo-5H, 6H,8H-imidazo[1,5-a]pyrazine-1-carboxylic acid [0195] A 100 mL vial was charged with 7-(tert-butyl) 1-ethyl 2-(1-((R)-2- hydroxypropyl)-1H-indazol-5-yl)-6-methyl-3-oxo-2,5,6,8-tetra hydroimidazo[1,5-a]pyrazine- 1,7(3H)-dicarboxylate (400 mg, 0.800 mmol, 1.00 eq.), NaOH (80 mg, 2.00 mmol, 2.50 eq.), H 2 O (5 mL) and EtOH (20 mL). The mixture was stirred for overnight at 60 °C and then concentrated under reduced pressure. The mixture was diluted with water (50 mL) and neutralized to pH 7 with hydrochloric acid (1.0 mol/L). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 7-(tert-butoxycarbonyl)-2-(1-((R)-2-hydroxypropyl)-1H-indazo l-5-yl)-6-methyl-3- oxo-2,3,5,6,7,8-hexahydroimidazo[1,5-a]pyrazine-1-carboxylic acid (350 mg, crude) as a yellow oil. LCMS (ESI, m/z): 472 [M+H] + . tert-butyl 2-{1-[(2R)-2-hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-1-({ [2-(pyrimidin- 2-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazin e-7-carboxylate [0196] A 100 mL vial were added 7-(tert-butoxycarbonyl)-2-{1-[(2R)-2- hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-5H,6H,8H-imidazo[ 1,5-a]pyrazine-1- carboxylic acid (350 mg, 0.742 mmol, 1.00 eq.), 1-[2-(pyrimidin-2-yl)phenyl]methanamine hydrochloride (198 mg, 0.890 mmol, 1.20 eq.), EDCI (171 mg, 0.890 mmol, 1.20 eq.), HOBT (120 mg, 0.890 mmol, 1.20 eq.), DIEA (480 mg, 3.71 mmol, 5.00 eq.) and DMF (20 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with CH 2 Cl 2 :MeOH (10:1) to afford tert-butyl 2-{1-[(2R)-2-hydroxypropyl]indazol-5-yl}-6- methyl-3-oxo-1-({[2-(pyrimidin-2-yl)phenyl]methyl}carbamoyl) -5H,6H,8H-imidazo[1,5- a]pyrazine-7-carboxylate (200 mg, 42% yield) as a yellow solid. LCMS (ESI, m/z):639 [M+H] + . 2-{1-[(2R)-2-hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-N-{[ 2-(pyrimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide trifluoroacetic acid salt [0197] A 100 mL round bottom flask was charged with tert-butyl 2-{1-[(2R)-2- hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-1-({[2-(pyrimidin -2- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (200 mg, 0.313 mmol, 1.00 eq.), TFA (1 mL) and DCM (5 mL). The mixture was stirred for 2 h at rt under an air atmosphere and then concentrated under reduced pressure to afford 2-{1- [(2R)-2-hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-N-{[2-(py rimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide trifluoroacetic acid salt (205 mg, crude) as a yellow oil. LCMS (ESI, m/z): 539 [M-TFA+H] + . (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{1-[(2R)-2-hy droxypropyl]indazol-5- yl}-6-methyl-3-oxo-N-{[2-(pyrimidin-2-yl)phenyl]methyl}-5H,6 H,8H-imidazo [1,5- a]pyrazine-1-carboxamide (91a) and (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2- {1-[(2R)-2-hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-N-{[2- (pyrimidin-2- yl)phenyl]methyl}-5H,6H,8H-imidazo [1,5-a]pyrazine-1-carboxamide (91b) [0198] A 40 mL vial were added 2-{1-[(2R)-2-hydroxypropyl]indazol-5-yl}-6- methyl-3-oxo-N-{[2-(pyrimidin-2-yl)phenyl]methyl}-5H,6H,7H,8 H-imidazo[1,5-a]pyrazine- 1-carboxamide trifluoroacetic acid salt (182 mg, 0.278 mmol, 1.00 eq.), 4-bromo-3- (trifluoromethyl)benzoic acid (89.9 mg, 0.334 mmol, 1.20 eq.), EDCI (64.1 mg, 0.334 mmol, 1.20 eq.), HOBT (45.2 mg, 0.334 mmol, 1.20 eq.), DIEA (180 mg, 1.39 mmol, 5.00 eq.) and DMF (10 mL) at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with CH 2 Cl 2 :MeOH (10:1) to afford the crude product. The crude product was purified by prep-CHIRAL-HPLC with the following conditions: Column: CHIRALPAK IF, 2 x 25 cm, 5 ^m; Mobile Phase A: MtBE(0.5% 2M NH 3 -MeOH)--HPLC, Mobile Phase B: IPA--HPLC; Flow rate: 11.5 mL/min; Gradient: 50% B to 50% B in 26 min; Wave Length: 220/254 nm to afford the final products. [0199] (6R*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{1-[(2R)-2- hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-N-{[2-(pyrimidin- 2-yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (91a) (the first elution, 16.0 mg, 7.3% yield) as a white solid. LCMS (ESI, m/z): 789 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.29 (d, J = 8.0 Hz, 2H), 8.03-8.01 (m, 1H), 7.90-7.83 (m, 2H), 7.75 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.50-7.43 (m, 4H), 6.99-6.92 (m, 4H), 5.22 (s, 1H), 4.70 (d, J = 8.0 Hz, 1H), 4.53 (s, 1H), 4.36 (d, J = 6.0 Hz, 1H), 4.22-4.12 (m, 2H), 4.03-3.97 (m, 1H), 3.87 (d, J = 6.0 Hz, 1H), 3.74 (d, J = 4.0 Hz, 1H), 2.33 (s, 1H), 1.43 (d, J = 4.0 Hz, 3H), 1.28-1.24 (m, 3H). [0200] (6S*)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-{1-[(2R)-2- hydroxypropyl]indazol-5-yl}-6-methyl-3-oxo-N-{[2-(pyrimidin- 2-yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (91b) (the second elution, 19.7 mg, 9.0% yield) as a white solid. LCMS (ESI, m/z):789 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.29 (d, J = 8.0 Hz, 2H), 8.03-8.01 (m, 1H), 7.90-7.83 (m, 2H), 7.75 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.50-7.43 (m, 4H), 6.99-6.92 (m, 4H), 5.22 (s, 1H), 4.70 (d, J = 8.0 Hz, 1H), 4.53 (s, 1H), 4.36 (d, J = 6.0 Hz, 1H), 4.22-4.12 (m, 2H), 4.03-3.97 (m, 1H), 3.87 (d, J = 6.0 Hz, 1H), 3.74 (d, J = 4.0 Hz, 1H), 2.33 (s, 1H), 1.43 (d, J = 4.0 Hz, 3H), 1.28-1.24 (m, 3H). Example 15 (6R*)-2-(2-amino-1,3-benzoxazol-5-yl)-7-[4-bromo-3-(trifluor omethyl)benzoyl]-6-methyl-3- oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H,8H-imidazo [1,5-a]pyrazine-1- carboxamide (93a) and (6S*)-2-(2-amino-1,3-benzoxazol-5-yl)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,8H-imidazo [1,5-a]pyrazine-1-carboxamide (93b) benzyl N-(5-bromo-2-hydroxyphenyl)carbamate [0201] A 250 mL round-bottom flask was charged with 2-amino-4-bromophenol (5.00 g, 26.6 mmol, 1.00 eq.), benzyl chloroformate (5.44 g, 31.9 mmol, 1.20 eq.), sodium bicarbonate (6.70 g, 79.8 mmol, 3.00 eq.), water (50 mL) and tetrahydrofuran (100 mL) at 0 °C. The mixture was stirred for overnight at rt. The reaction was quenched with water (150 mL). The mixture was extracted with ethyl acetate (3 x 250 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:5) to afford benzyl N-(5-bromo-2-hydroxyphenyl)carbamate (5.11 g, 60% yield) as a pink solid. LCMS (ESI, m/z): 322 [M+H] + . benzyl N-[2-(benzyloxy)-5-bromophenyl]carbamate [0202] A 250 mL round-bottom flask was charged with benzyl N-(5-bromo-2- hydroxyphenyl)carbamate (5.00 g, 15.5 mmol, 1.00 eq.), BnBr (3.19 g, 18.6 mmol, 1.20 eq.), potassium carbonate (6.43 g, 46.6 mmol, 3.00 eq.) and acetonitrile (130 mL) at 0 °C. The mixture was stirred for 18 h at rt and then concentrated under reduced pressure.. The reaction was quenched with water (150 mL). The mixture was extracted with ethyl acetate (3 x 250 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:6) to afford benzyl N-[2-(benzyloxy)-5- bromophenyl]carbamate (4.79 g, 75% yield) as a pink solid. LCMS (ESI, m/z): 412 [M+H] + . 4-(benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenylboronic acid [0203] A 250 mL round bottom flask was charged with benzyl N-[2-(benzyloxy)- 5-bromophenyl]carbamate (5.00 g, 12.1 mmol, 1.00 eq.), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (5.48 g, 24.3 mmol, 2.00 eq.), Pd(dppf)Cl 2 (0.890 g, 1.21 mmol, 0.10 eq.), potassium acetate (3.57 g, 36.4 mmol, 3.00 eq.) and 1,4-dioxane (150 mL). The mixture was stirred for overnight at 80 °C, concentrated under reduced pressure and diluted with water (150 mL). The mixture was extracted with ethyl acetate (3 x 250 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography with following condition: Column: Agela C 18 Column, 120 g; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 40 mL/min; Gradient: 0% B to 100% B in 40 min; Wave Length: 220 nm to afford 4-(benzyloxy)-3- {[(benzyloxy)carbonyl]amino}phenylboronic acid (2.11 g, 46% yield) as a white solid. LCMS (ESI, m/z): 378 [M+H] + . 7-tert-butyl 1-ethyl 2-[4-(benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenyl]-6-met hyl- 3-oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarboxylate [0204] A 100 mL round bottom flask was charged with 7-tert-butyl 1-ethyl 6- methyl-3-oxo-2H,5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarbox ylate (1.00 g, 3.07 mmol, 1.00 eq.), 4-(benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenylboronic acid (1.39 g, 3.69 mmol, 1.20 eq.), Cu(OTf) 2 (1.11 g, 3.07 mmol, 1.00 eq.), pyridine (0.729 g, 9.22 mmol, 3.00 eq.) and DMF (50 mL). The mixture was stirred for 3 h at 70 °C under an oxygen atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford 7-tert-butyl 1-ethyl 2-[4-(benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenyl]-6-met hyl-3-oxo-5H,6H,8H- imidazo[1,5-a]pyrazine-1,7-dicarboxylate (1.34 g, 66% yield) as a pink solid. LCMS (ESI, m/z): 657 [M+H] + . 2-[4-(benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenyl]-7-(te rt-butoxycarbonyl)-6- methyl-3-oxo-5H,6H,8H-imidazo [1,5-a]pyrazine-1-carboxylic acid [0205] A 100 mL round bottom flask was charged with 7-tert-butyl 1-ethyl 2-[4- (benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenyl]-6-methyl-3 -oxo-5H,6H,8H- imidazo[1,5-a]pyrazine-1,7-dicarboxylate (1.00 g, 1.52 mmol, 1.00 eq.), sodium hydroxide (0.120 g, 3.05 mmol, 2.00 eq.), water (20 mL) and MeOH (40 mL) at rt. The mixture was stirred for 2 h at 60 °C and acidified to pH 6 with a hydrochloric acid aqueous solution (1 mol/L). The precipitated solids were collected by filtration and washed with water (3 x 50 mL). The resulting solid was dried to afford 2-[4-(benzyloxy)-3- {[(benzyloxy)carbonyl]amino}phenyl]-7-(tert-butoxycarbonyl)- 6-methyl-3-oxo-5H,6H,8H- imidazo [1,5-a]pyrazine-1-carboxylic acid (312 mg, 33% yield) as an orange solid. LCMS (ESI, m/z): 629 [M+H] + .
tert-butyl 2-[4-(benzyloxy)-3-{[(benzyloxy)carbonyl]amino}phenyl]-6-met hyl-3-oxo-1- ({[2-(pyrimidin-4-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imida zo[1,5-a]pyrazine-7- carboxylate [0206] A 100 mL round bottom flask was charged with 2-[4-(benzyloxy)-3- {[(benzyloxy)carbonyl]amino}phenyl]-7-(tert-butoxycarbonyl)- 6-methyl-3-oxo-5H,6H,8H- imidazo[1,5-a] pyrazine-1-carboxylic acid (1.00 g, 1.59 mmol, 1.00 eq.), 1-[2-(pyrimidin-4- yl)phenyl]methanamine hydrochloride (424 mg, 1.91 mmol, 1.20 eq.), EDCI (457 mg, 2.39 mmol, 1.50 eq.), HOBT (322 mg, 2.39 mmol, 1.50 eq.), DIEA (1.03 g, 7.96 mmol, 5.00 eq.) and DMF (40 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (3:2) to afford tert-butyl 2-[4-(benzyloxy)-3- {[(benzyloxy)carbonyl]amino}phenyl]-6-methyl-3-oxo-1-({[2-(p yrimidin-4- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (605 mg, 48% yield) as a brown solid. LCMS (ESI, m/z): 796 [M+H] + .
tert-butyl 2-(3-amino-4-hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyrimidin -4- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate [0207] A 100 mL round bottom flask was charged with tert-butyl 2-(3- {benzyl[(benzyloxy)carbonyl]amino}-4-(benzyloxy)phenyl)-6-me thyl-3-oxo-1-({[2- (pyrimidin-4-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1, 5-a]pyrazine-7-carboxylate (500 mg, 0.564 mmol, 1.00 eq.), 10% Pd/C (60 mg) and ethyl acetate (50 mL). The mixture was stirred for 2 days at 60 °C under a hydrogen atmosphere (2-3 atm). The solids were filtered off, and the filter cake was washed with ethyl acetate (3 x 50 mL). The filtrate was concentrated under reduced pressure to afford tert-butyl 2-(3-amino-4-hydroxyphenyl)-6- methyl-3-oxo-1-({[2-(pyrimidin-4-yl)phenyl]methyl}carbamoyl) -5H,6H,8H-imidazo[1,5- a]pyrazine-7-carboxylate (173 mg, 54% yield) as a yellow solid. LCMS (ESI, m/z): 572 [M+H] + . tert-butyl 2-(2-amino-1,3-benzoxazol-5-yl)-6-methyl-3-oxo-1-({[2-(pyrim idin-4- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate [0208] A 100 mL round bottom flask was charged with tert-butyl 2-(3-amino-4- hydroxyphenyl)-6-methyl-3-oxo-1-({[2-(pyrimidin-4-yl)phenyl] methyl}carbamoyl)- 5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate (110 mg, 0.192 mmol, 1.00 eq.), 1- (imidazole-1-carboximidoyl)imidazole (62.0 mg, 0.384 mmol, 2.00 eq.), ZnCl 2 (13.1 mg, 0.10 mmol, 0.50 eq.) and tetrahydrofuran (50 mL). The solution was refluxed overnight under a nitrogen atmosphere. The reaction was quenched with water (10 mL). The mixture was concentrated under reduced pressure and then diluted with water (100 mL). The mixture was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane:methyl alcohol (10:1) to afford tert-butyl 2-(2-amino-1,3-benzoxazol- 5-yl)-6-methyl-3-oxo-1-({[2-(pyrimidin-4-yl)phenyl]methyl}ca rbamoyl)-5H,6H,8H-imidazo [1,5-a]pyrazine-7-carboxylate (83.0 mg, 72% yield) as a yellow solid. LCMS (ESI, m/z): 597 [M+H] + . 2-(2-amino-1,3-benzoxazol-5-yl)-6-methyl-3-oxo-N-{[2-(pyrimi din-4-yl)phenyl]methyl}- 5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt [0209] A 100 mL round bottom flask was charged with tert-butyl 2-(2-amino-1,3- benzoxazol-5-yl)-6-methyl-3-oxo-1-({[2-(pyrimidin-4-yl)pheny l]methyl}carbamoyl)- 5H,6H,8H-imidazo[1,5-a]pyrazine-7-carboxylate (83.0 mg, 0.139 mmol, 1.00 eq.), dichloromethane (30 mL) and trifluoroacetic acid (6 mL). The solution was stirred for 2 h at rt and then concentrated under reduced pressure to afford 2-(2-amino-1,3-benzoxazol-5-yl)- 6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H,7H ,8H-imidazo[1,5- a]pyrazine-1-carboxamide trifluoroacetic acid salt (88.6 mg, crude) as a yellow oil. LCMS (ESI, m/z): 497 [M+H-TFA] + . (6R*)-2-(2-amino-1,3-benzoxazol-5-yl)-7-[4-bromo-3-(trifluor omethyl)benzoyl]-6- methyl-3-oxo-N-{[2-(pyrimidin-4-yl)phenyl]methyl}-5H,6H,8H-i midazo [1,5-a]pyrazine- 1-carboxamide (93a) and (6S*)-2-(2-amino-1,3-benzoxazol-5-yl)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,8H-imidazo [1,5-a]pyrazine-1-carboxamide (93b) [0210] A 100 mL round bottom flask was charged with 2-(2-amino-1,3- benzoxazol-5-yl)-6-methyl-3-oxo-N-{[2-(pyrimidin-4-yl)phenyl ]methyl}-5H,6H,7H,8H- imidazo[1,5-a]pyrazine-1-carboxamide trifluoroacetic acid salt (88.6 mg, 0.145 mmol, 1.00 eq.), 4-bromo-3-(trifluoromethyl)benzoic acid (46.8 mg, 0.174 mmol, 1.20 eq.), EDCI (41.7 mg, 0.217 mmol, 1.50 eq.), HOBT (29.4 mg, 0.217 mmol, 1.50 eq.), DIEA (93.7 mg, 0.725 mmol, 5.00 eq.) and DMF (20 mL). The mixture was stirred for overnight at 60 °C. The reaction was quenched with water (60 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with saturated sodium chloride solution (3 x 30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (9:1) to afford the crude product. The product was separated by prep-CHIRAL HPLC: Column: Column: CHIRALPAK IF, 2 x 25 cm, 5 ^m; Mobile Phase A: MtBE (0.5% 2M NH 3 -MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 11 mL/min; Gradient: 50% B to 50% B in 32 min; Wave Length: 220/254 nm to afford the final products. [0211] (6R*)-2-(2-amino-1,3-benzoxazol-5-yl)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,8H-imidazo [1,5-a]pyrazine-1-carboxamide (93a) (the first elution, 5.9 mg, 5.5% yield) as a brown solid. LCMS (ESI, m/z): 747 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 8.77-8.62 (m, 2H), 7.82 (d, J = 8.0 Hz, 2H), 7.55-7.34 (m, 6H), 7.22 (d, J = 1.7 Hz, 1H), 6.88 (q, J = 8.5 Hz, 2H), 6.71 (s, 1H), 5.71 (s, 2H), 5.34 (s, 1H), 4.66 (d, J = 19.1 Hz, 1H), 4.14- 4.22 (m, 2H), 3.87 (d, J = 12.8 Hz, 1H), 3.73 (d, J = 12.9 Hz, 1H), 1.43 (d, J = 6.9 Hz, 3H). [0212] (6S*)-2-(2-amino-1,3-benzoxazol-5-yl)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-6-methyl-3-oxo-N-{[2-(pyrimidin-4- yl)phenyl]methyl}- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxamide (93b) (the second elution, 4.7 mg, 4.3% yield) as a brown solid. LCMS (ESI, m/z): 747 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 8.78-8.63 (m, 2H), 7.82 (d, J = 8.0 Hz, 2H), 7.56-7.33 (m, 6H), 7.22 (s, 1H), 7.01-6.81 (m, 2H), 6.71 (s, 1H), 5.74 (s, 2H), 5.76 (s, 1H), 4.66 (d, J = 18.8 Hz, 1H), 4.29 (td, J = 14.0, 6.1 Hz, 2H), 3.87 (d, J = 12.9 Hz, 1H), 3.73 (d, J = 12.3 Hz, 1H), 1.43 (d, J = 6.9 Hz, 3H).
Example 16 6-(benzyloxymethyl)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2 -[4-(cyclopropoxy)phenyl]- 3-oxo-N-[(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imid azo[1,5-a]pyrazine-1- carboxamide (130) ^ Ethyl 6-chloro-2-(4-cyclopropoxyphenyl)-3-oxoimidazo[1,5-a]pyrazin e-1-carboxylate [0213] A mixture of ethyl 6-chloro-3-oxo-2H-imidazo[1,5-a]pyrazine-1- carboxylate (5.00 g, 20.7 mmol, 1.00 eq.), 4-cyclopropoxyphenylboronic acid (3.68 g, 20.7 mmol, 1.00 eq.), pyridine (8.18 g, 103 mmol, 5.00 eq.) and Cu(OAc) 2 (3.76 g, 20.7 mmol, 1.00 eq.) in DMF (50 mL) was stirred for 2 h at 60°C under an O 2 atmosphere. The reaction was quenched with water (500 mL). The mixture was extracted with ethyl acetate (3 x 200 mL). The organic layers were combined, washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford ethyl 6-chloro-2-(4-cyclopropoxyphenyl)-3-oxoimidazo[1,5-a]pyrazin e-1- carboxylate (2.1 g, 27% yield) as a yellow solid. LCMS (ESI, m/z): 374 [M+H] + . Ethyl 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxoimidazo[ 1,5-a]pyrazine-1- carboxylate [0214] A mixture of ethyl 6-chloro-2-(4-cyclopropoxyphenyl)-3-oxoimidazo[1,5- a]pyrazine-1-carboxylate (1.60 g, 4.28 mmol, 1.00 eq.), [(benzyloxy)methyl]trifluoro-λ4- borane potassium (1.27 g, 5.56 mmol, 1.30 eq.), bis(adamantan-1-yl)(butyl)phosphane (0.310 g, 0.856 mmol, 0.20 eq.), Pd(OAc) 2 (0.190 g, 0.856 mmol, 0.20 eq.), Cs 2 CO 3 (4.18 g, 12.8 mmol, 3.00 eq.), H 2 O (3 mL) and 1,4-dioxane (15 mL) was irradiated with microwave radiation for 3 h at 130 °C under a nitrogen atmosphere and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (10:1) to afford ethyl 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3- oxoimidazo[1,5-a]pyrazine-1-carboxylate (330 mg, 17% yield) as a yellow solid. LCMS (ESI, m/z): 460 [M+H] + . 7-tert-butyl 1-ethyl 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-5H,6H,8 H- imidazo[1,5-a]pyrazine-1,7-dicarboxylate [0215] To a stirred mixture of ethyl 6-[(benzyloxy)methyl]-2-(4- cyclopropoxyphenyl)-3-oxoimidazo[1,5-a]pyrazine-1-carboxylat e (330 mg, 0.718 mmol, 1.00 eq.) in MeOH (10 mL) was added NaBH 4 (272 mg, 7.18 mmol, 10.0 eq.) in portions at 0°C under a nitrogen atmosphere. The mixture was stirred for overnight at rt. To the mixture was added NaHCO 3 (302 mg, 3.59 mmol, 5.00 eq.) and (Boc) 2 O (784 mg, 3.59 mmol, 5.00 eq.). The mixture was stirred overnight at rt and then concentrated under reduced pressure. The residue was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (ethyl acetate:petroleum ether = 2:3) to afford 7-tert-butyl 1-ethyl 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo- 5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarboxylate (200 mg, 49% yield) as a yellow solid. LCMS (ESI, m/z): 564 [M+H] + . 6-[(benzyloxy)methyl]-7-(tert-butoxycarbonyl)-2-(4-cycloprop oxyphenyl)-3-oxo- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxylic acid [0216] A 100 mL round-bottom flask was charged with 7-tert-butyl 1-ethyl 6- [(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-5H,6H,8H- imidazo[1,5-a]pyrazine- 1,7-dicarboxylate (200 mg, 0.355 mmol, 1.00 eq.), H 2 O (10 mL) and NaOH (28.4 mg, 0.710 mmol, 2.00 eq.) at rt. The mixture was stirred for overnight at 60 °C. The mixture was acidified to pH 4 with acetic acid. The mixture was extracted with ethyl acetate (3 x 20 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (ethyl acetate:petroleum ether = 1:1) to afford 6-[(benzyloxy)methyl]-7-(tert- butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-3-oxo-5H,6H,8H-imid azo[1,5-a]pyrazine-1- carboxylic acid (150 mg, 79% yield) as a yellow solid. LCMS (ESI, m/z): 536 [M+H] + . tert-butyl 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-1-({[2- (pyrimidin-2- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate [0217] A 50 mL round-bottom flask was charged with 6-[(benzyloxy)methyl]-7- (tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-3-oxo-5H,6H,8 H-imidazo[1,5-a]pyrazine- 1-carboxylic acid (150 mg, 0.280 mmol, 1.00 eq.), 1-[2-(pyrimidin-2-yl)phenyl]methanamine hydrochloride (62.1 mg, 0.280 mmol, 1.00 eq.), EDCI (69.9 mg, 0.364 mmol, 1.30 eq.), HOBT (49.2 mg, 0.364 mmol, 1.30 eq.), DIEA (109 mg, 0.841 mmol, 3.00 eq.) and DMF (5 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (CH 2 Cl 2 :MeOH = 10:1) to afford tert-butyl 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-1-({[2- (pyrimidin-2-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1, 5-a]pyrazine-7-carboxylate (122 mg, 62% yield) as a white solid. LCMS (ESI, m/z): 703 [M+H] + . 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-N-{[2-( pyrimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide [0218] A 40 mL vial was charged with tert-butyl 6-[(benzyloxy)methyl]-2-(4- cyclopropoxyphenyl)-3-oxo-1-({[2-(pyrimidin-2-yl)phenyl]meth yl}carbamoyl)-5H,6H,8H- imidazo[1,5-a]pyrazine-7-carboxylate (122 mg, 0.174 mmol, 1.00 eq.), TBSOTf (459 mg, 1.74 mmol, 10.0 eq.), 2,6-lutidine (186 mg, 1.74 mmol, 10.0 eq.) and DCM (5 mL) at rt. The mixture was stirred for 30 min at rt and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (10:1) to afford 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-N-{[2-( pyrimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide (90 mg, 86% yield) as a yellow solid. LCMS (ESI, m/z): 603 [M+H] + . 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-N-{[2-( pyrimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide [0219] A mixture of 6-[(benzyloxy)methyl]-2-(4-cyclopropoxyphenyl)-3-oxo-N- {[2-(pyrimidin-2-yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a ]pyrazine-1-carboxamide (90.0 mg, 0.149 mmol, 1.00 eq.), 4-bromo-3-(trifluoromethyl)benzoic acid (48.2 mg, 0.179 mmol, 1.20 eq.), HATU (68.1 mg, 0.179 mmol, 1.20 eq.) and DIEA (57.9 mg, 0.447 mmol, 3.00 eq.) in DMF (5 mL) was stirred for overnight at rt. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by prep- HPLC with the following conditions: Column: XBridge Prep Phenyl OBD Column, 19 x 150 mm, 5^m; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 55% B to 68% B in 7 min; Wave Length: 220 nm to afford 6-[(benzyloxy)methyl]-7-[4-bromo-3-(trifluoromethyl)benzoyl] -2-(4- cyclopropoxyphenyl)-3-oxo-N-{[2-(pyrimidin-2-yl)phenyl]methy l}-5H,6H,8H-imidazo[1,5- a]pyrazine-1-carboxamide (42.0 mg, 33% yield) as a white solid. LCMS (ESI, m/z): 853 [M+H] + . 1 H NMR (300 MHz, CDCl3) į 8.59 (s, 2H), 8.10 (d, J = 4.2 Hz, 1H), 7.84-7.70 (m, 2H), 7.43 (d, J = 8.3 Hz, 4H), 7.31 (t, J = 8.4 Hz, 4H), 7.18 (d, J = 5.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 3H), 6.72 (d, J = 8.4 Hz, 2H), 4.64-4.36 (m, 6H), 3.98-3.43 (m, 6H), 0.71 (d, J = 6.0 Hz, 2H), 0.58 (s, 2H). Example 17 7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-[4-(cyclopropoxy)ph enyl]-6-(hydroxymethyl)-3- oxo-N-[(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidaz o[1,5-a]pyrazine-1- carboxamide (131) [0220] A mixture of 6-[(benzyloxy)methyl]-7-[4-bromo-3- (trifluoromethyl)benzoyl]-2-(4-cyclopropoxyphenyl)-3-oxo-N-{ [2-(pyrimidin-2- yl)phenyl]methyl}-5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxam ide (130) (13.0 mg, 0.0150 mmol, 1.00 eq.) and CF 3 COOH (1 mL) was stirred for overnight at 60 °C and then concentrated under reduced pressure. The crude product was purified by prep-HPLC with the following conditions: Column: XSelect CSH Prep C 18 OBD Column, 19 x 250 mm, 5 ^m; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 ), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 55% B to 68% B in 10 min; Wave Length: 254 nm to afford 7-[4-bromo- 3-(trifluoromethyl)benzoyl]-2-(4-cyclopropoxyphenyl)-6-(hydr oxymethyl)-3-oxo-N-{[2- (pyrimidin-2-yl)phenyl]methyl}-5H,6H,8H-imidazo[1,5-a]pyrazi ne-1-carboxamide (131) (4.40 mg, 37% yield) as a white solid. LCMS (ESI, m/z): 763 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ) į 8.64-8.51 (m, 2H), 8.09 (s, 1H), 7.89-7.73 (m, 2H), 7.85-7.79 (m, 4H), 7.16 (t, J = 4.8 Hz, 2H), 7.06 (d, J = 8.6 Hz, 4H), 6.70 (d, J = 8.5 Hz, 2H), 4.51-4.39 (m, 4H), 3.98-3.43 (m, 9H), 1.25 (s,5H), 0.88 (s,1H), 0.71-0.69 (m, 2H), 0.57 (s, 2H).
Example 18 7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-[4-(cyclopropoxy)ph enyl]-6-(morpholinomethyl)- 3-oxo-N-[(2-pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imid azo[1,5-a]pyrazine-1- carboxamide (132) and separation into its enantiomers rac-(6S)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-2-[4-(cyclopropoxy)phenyl]-6-(morp holinomethyl)-3-oxo-N-[(2- pyrimidin-2-ylphenyl)methyl]-6,8-dihydro-5H-imidazo[1,5-a]py razine-1-carboxamide (132a) and rac-(6R)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-[4-(cyclop ropoxy)phenyl]-6- (morpholinomethyl)-3-oxo-N-[(2-pyrimidin-2-ylphenyl)methyl]- 6,8-dihydro-5H- imidazo[1,5-a]pyrazine-1-carboxamide (132b)
7-tert-butyl 1-ethyl 2-(4-cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo- 5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarboxylate [0221] A 100 mL microwave tube was charged with ethyl 6-chloro-2-(4- cyclopropoxyphenyl)-3-oxoimidazo [1,5-a]pyrazine-1-carboxylate (600 mg, 1.60 mmol, 1.00 eq.), 4-[(trifluoro-λ4-boranyl)methyl] morpholine potassium (664 mg, 3.21 mmol, 2.00 eq.), 1,4-dioxane (30 mL), Cs 2 CO 3 (1046 mg, 3.21 mmol, 2.00 eq.), Pd(OAc) 2 (18.0 mg, 0.0800 mmol, 0.05 eq.), water (10 mL) and bis(adamantan-1-yl)(butyl)phosphane (57.6 mg, 0.161 mmol, 0.10 eq.) under nitrogen. The mixture was irradiated with microwave radiation for 3 h at 130 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford ethyl 2-(4-cyclopropoxyphenyl)-6-(morpholin-4- ylmethyl)-3-oxoimidazo[1,5-a]pyrazine-1-carboxylate (300 mg, 42% yield) as a yellow solid. LCMS (ESI, m/z): 439 [M+H] + . 7-tert-butyl 1-ethyl 2-(4-cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo- 5H,6H,8H-imidazo[1,5-a]pyrazine-1,7-dicarboxylate [0222] A 100 mL round bottom flask was charged with ethyl 2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxoimidazo[1, 5-a]pyrazine-1-carboxylate (300 mg, 0.684 mmol, 1.00 eq.), Boc 2 O (298 mg, 1.37 mmol, 2.00 eq.) and methanol (50 mL). NaBH 4 (77.7 mg, 2.05 mmol, 3.00 eq.) was added in portions at 0 °C. The solution was stirred for 2 h at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford 7-tert-butyl 1-ethyl 2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-5H,6H,8H- imidazo[1,5-a]pyrazine- 1,7-dicarboxylate (200 mg, 53% yield) as a white solid. LCMS (ESI, m/z): 543 [M+H] + . 7-(tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-(morpholi n-4-ylmethyl)-3-oxo- 5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxylic acid [0223] A 40 mL vial was charged with 7-tert-butyl 1-ethyl 2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-5H,6H,8H- imidazo[1,5-a]pyrazine- 1,7-dicarboxylate (200 mg, 0.369 mmol, 1.00 eq.), NaOH (29.5 mg, 0.738 mmol, 2.00 eq.), water (10 mL) and methanol (10 mL). The solution was stirred for 2 h at 60 °C and then diluted with water (50 mL). The pH value of the mixture was adjusted to 4 with HCl (aq. 1 mol/L). The aqueous phase was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 7-(tert-butoxycarbonyl)-2-(4-cyclopropoxyphenyl)-6-(morpholi n- 4-ylmethyl)-3-oxo-5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxyl ic acid (150 mg, crude) as a white solid. LCMS (ESI, m/z): 515 [M+H] + . tert-butyl 2-(4-cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-1-({ [2-(pyrimidin- 2-yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazin e-7-carboxylate [0224] A 40 mL vial was charged with 7-(tert-butoxycarbonyl)-2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-5H,6H,8H- imidazo[1,5-a]pyrazine-1- carboxylic acid (150 mg, 0.292 mmol, 1.00 eq.), 1-[2-(pyrimidin-2-yl)phenyl]methanamine hydrochloride (71.1 mg, 0.321 mmol, 1.10 eq.), HOBT (59.1 mg, 0.438 mmol, 1.50 eq.), EDCI (83.8 mg, 0.438 mmol, 1.50 eq.), DIEA (151 mg, 1.17 mmol, 4.00 eq.) and DMF (10 mL). The solution was stirred for overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with water (3 x 100mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford tert-butyl 2-(4-cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-1-({ [2-(pyrimidin-2- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (100 mg, 50% yield) as a white solid. LCMS (ESI, m/z): 682 [M+H] + . 2-(4-cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-N-{[ 2-(pyrimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide trifluoroacetic acid salt [0225] A 100 mL round bottom flask was charged with tert-butyl 2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-1-({[2-(p yrimidin-2- yl)phenyl]methyl}carbamoyl)-5H,6H,8H-imidazo[1,5-a]pyrazine- 7-carboxylate (100 mg, 0.147 mmol, 1.00 eq.), dichloromethane (20 mL) and trifluoroacetic acid (5 mL). The solution was stirred for 3 h at rt and then concentrated under reduced pressure to afford 2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-N-{[2-(py rimidin-2- yl)phenyl]methyl}-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1-carbo xamide trifluoroacetic acid salt (100 mg, crude) as a light yellow solid. LCMS (ESI, m/z): 582 [M+H-TFA] + . rac-(6R)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-(4-cyclopr opoxyphenyl)-6- (morpholin-4-ylmethyl)-3-oxo-N-{[2-(pyrimidin-2-yl)phenyl]me thyl}-5H,6H,8H- imidazo[1,5-a]pyrazine-1-carboxamide and rac-(6S)-7-[4-bromo-3- (trifluoromethyl)benzoyl]-2-(4-cyclopropoxyphenyl)-6-(morpho lin-4-ylmethyl)-3-oxo-N- {[2-(pyrimidin-2-yl)phenyl]methyl}-5H,6H,8H-imidazo[1,5-a]py razine-1-carboxamide [0226] A 40 mL vial was charged with 2-(4-cyclopropoxyphenyl)-6-(morpholin- 4-ylmethyl)-3-oxo-N-{[2-(pyrimidin-2-yl)phenyl]methyl}-5H,6H ,7H,8H-imidazo[1,5- a]pyrazine-1-carboxamide trifluoroacetic acid salt (100 mg, 0.144 mmol, 1.00 eq.), 4-bromo- 3-(trifluoromethyl)benzoic acid (47.5 mg, 0.176 mmol, 1.22 eq.), HOBT (23.9 mg, 0.176 mmol, 1.22 eq.), EDCI (33.8 mg, 0.176 mmol, 1.22 eq.), DIEA (76.0 mg, 0.588 mmol, 4.08 eq.) and DMF (10 mL). The solution was stirred for overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with EA (3 x 100 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (ethyl acetate:petroleum ether = 3:1) to afford the crude product. The crude product was purified by prep-HPLC with the following conditions: Column: CHIRAL ART Amylose-SA, 2 x 25 cm, 5 ^m; Mobile Phase A: MtBE (0.5% 2M NH 3 -MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL/min; Gradient: 25% B to 25% B in 16 min; Wave Length: 220/254 nm to afford [0227] rac-(6R)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-N-{[2-(py rimidin-2- yl)phenyl]methyl}-5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxam ide (132a) (the first elution, 22.5 mg, 18% yield) as a light yellow solid. LCMS (ESI, m/z): 832 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.59 (d, J = 4.8 Hz, 2H), 8.18-8.06 (m, 1H), 7.98-7.80 (m, 2H), 7.45 (d, J = 4.2 Hz, 4H), 7.17 (t, J = 4.9 Hz, 1H), 7.13-6.93 (m, 3H), 6.70 (d, J = 8.3 Hz, 2H), 5.50 (s, 1H), 5.13 (s, 1H), 4.47 (m 3H), 3.98 (d, J = 13.1 Hz, 1H), 3.71 (s, 5H), 3.43 (s, 1H), 2.70-2.50 (m, 5H), 0.71 (d, J = 6.3 Hz, 2H), 0.57 (s, 2H). [0228] rac-(6S)-7-[4-bromo-3-(trifluoromethyl)benzoyl]-2-(4- cyclopropoxyphenyl)-6-(morpholin-4-ylmethyl)-3-oxo-N-{[2-(py rimidin-2- yl)phenyl]methyl}-5H,6H,8H-imidazo[1,5-a]pyrazine-1-carboxam ide (132b) (the second elution, 23.8 mg, 19% yield) as a white solid. LCMS (ESI, m/z): 832 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) į 8.59 (d, J = 4.8 Hz, 2H), 8.18-8.05 (m, 1H), 7.96-7.78 (m, 2H), 7.45 (d, J = 3.8 Hz, 4H), 7.17 (t, J = 4.9 Hz, 1H), 7.13-6.90 (m, 3H), 6.70 (d, J = 8.4 Hz, 2H), 5.53 (s, 1H), 5.12 (s, 1H), 4.87-4.32 (m, 3H), 3.98 (d, J = 13.0 Hz, 1H), 3.75 (s, 5H), 3.43 (s, 1H), 3.02-2.33 (m, 5H), 0.71 (d, J = 6.4 Hz, 2H), 0.58 (s, 2H). Example 19 Intermediates I-1 to I-8 Synthesis of Intermediate I-1 [0229] A 40 mL vial was charged with 5-bromo-1H-indazole (500 mg, 2.54 mmol, 1.00 eq.), 2,2,2-trifluoroethyl trifluoromethanesulfonate (706 mg, 3.05 mmol, 1.20 eq.), K 2 CO 3 (701 mg, 5.08 mmol, 2.00 eq.) and DMF (20 mL). The mixture was stirred for overnight at 60 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:9) to afford 5-bromo-1-(2,2,2-trifluoroethyl)indazole (520 mg, 73% yield) as a white solid. LCMS (ESI, m/z): 279 [M+H] + . [0230] A 40 mL vial was charged with 5-bromo-1-(2,2,2-trifluoroethyl)indazole (400 mg, 1.43 mmol, 1.00 eq.), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2- dioxaborinane (971 mg, 4.30 mmol, 3.00 eq.), Pd(dppf)Cl 2 (105 mg, 0.143 mmol, 0.100 eq.), DMSO (20 mL) and AcOK (422 mg, 4.30 mmol, 3.00 eq.). The mixture was stirred for overnight at 60 °C under a nitrogen atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:8) to afford 5-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)-1-(2,2,2-trifluoroethyl)indazole (280 mg, 63% yield) as a white solid. LCMS (ESI, m/z): 313 [M+H] + . [0231] A 250 mL round-bottom flask was charged with 2-{[(tert- butoxycarbonyl)amino]methyl}phenylboronic acid (3.00 g, 11.9 mmol, 1.00 eq.), 2-chloro-4- (trifluoromethyl)pyrimidine (3.27 g, 17.9 mmol, 1.50 eq.), Pd(PPh 3 ) 4 (0.69 g, 0.597 mmol, 0.05 eq.), potassium carbonate (3.30 g, 23.9 mmol, 2.00 eq.) and 1,4-dioxane (150 mL). The mixture was stirred for overnight at 100 °C under a nitrogen atmosphere and then concentrated under reduced pressure. The reaction was quenched with water (100 mL) and extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:5) to afford tert-butyl N-({2-[4- (trifluoromethyl)pyrimidin-2-yl]phenyl}methyl)carbamate (1.80 g, 42% yield) as a white solid. LCMS (ESI, m/z): 354 [M+H] + . [0232] A 100 mL round-bottom flask was charged with tert-butyl N-({2-[4- (trifluoromethyl)pyrimidin-2-yl]phenyl}methyl)carbamate (1.80 g, 5.09 mmol, 1.00 eq.), hydrogen chloride solution 4.0 M in 1,4-diethylene oxide (60 mL). The solution was stirred for 2 h at rt and then concentrated under reduced pressure to afford 1-{2-[4- (trifluoromethyl)pyrimidin-2-yl]phenyl}methanamine hydrochloride (1.45 g, crude) as a white solid. LCMS (ESI, m/z): 254 [M+H-HCl] + . Synthesis of Intermediate I-3 [0233] A mixture of 3-bromo-1H-pyrazole (5.00 g, 34.0 mmol, 1.00 eq.), 2,2,2- trifluoroethyl trifluoromethanesulfonate (11.8 g, 51.0 mmol, 1.50 eq.) and potassium carbonate (9.40 g, 68.0 mmol, 2.00 eq.) in DMF (50 mL) was stirred for overnight at 60 °C. The reaction was quenched with water (300 mL). The mixture was extracted with dichloromethane (3 x 200 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with dichloromethane:methanol (5:1) to afford 3-bromo-1-(2,2,2-trifluoroethyl) pyrazole (3.80 g, 49% yield) as a light yellow oil. LCMS (ESI, m/z): 229 [M+H] + . [0234] A 100 mL round-bottom flask 3-bromo-1-(2,2,2-trifluoroethyl)pyrazole (3.80 g, 16.6 mmol, 1.50 eq.), 2-{[(tert-butoxycarbonyl)amino]methyl}phenylboronic acid (2.78 g, 11.1 mmol, 1.00 eq.), Pd(PPh 3 ) 4 (1.28 g, 1.11 mmol, 0.100 eq.) and K 2 CO 3 (3.06 g, 22.1 mmol, 2.00 eq.), 1,4-dioxane (20 mL) and water (1 mL). The mixture was stirred for overnight at 100 °C under a nitrogen atmosphere. The reaction was quenched with water (80 mL). The mixture was extracted with dichloromethane (3 x 200 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with dichloromethane:methanol (5:1) to afford tert-butyl N- ({2-[1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenyl}methyl)carb amate (3.08 g, 78% yield) as a yellow oil. LCMS (ESI, m/z): 356 [M+H] + . [0235] A mixture of tert-butyl N-({2-[1-(2,2,2-trifluoroethyl)pyrazol-3- yl]phenyl}methyl)carbamate (980 mg, 0.844 mmol, 1.00 eq.) and HCl (gas) (10 mL, 4M in 1,4-dioxane) was stirred for 2 h at rt and then concentrated under reduced pressure to afford 1-{2-[1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenyl}methanamin e hydrochloride (1.06 g, crude) as a light yellow oil. LCMS (ESI, m/z): 256 [M+H-HCl] + . Synthesis of Intermediate I-4 [0236] A 100 mL round-bottom flask was charged with 5-bromo-1H-indazole (880 mg, 4.47 mmol, 1.00 eq.), (2R)-2-(trifluoromethyl)oxirane (500 mg, 4.47 mmol, 1.00 eq.), K 2 CO 3 (1.85 g, 13.4 mmol, 3.00 eq.) and DMF (20 mL). The mixture was stirred for overnight at 90 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford (2R)-3-(5-bromoindazol-1-yl)-1,1,1- trifluoropropan-2-ol (750 mg, 54% yield) as a light yellow solid. LCMS (ESI, m/z): 309 [M+H] + . [0237] A 250 mL round-bottom flask was charged with (2R)-3-(5-bromoindazol- 1-yl)-1,1,1-trifluoropropan-2-ol (550 mg, 1.78 mmol, 1.00 eq.), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (804 mg, 3.56 mmol, 2.00 eq.), Pd(pph 3 ) 2 Cl 2 (125 mg, 0.178 mmol, 0.10 eq.), KOAc (524 mg, 5.34 mmol, 3.0 eq.) and DMSO (10 mL). The mixture was stirred for overnight at 60 °C under a nitrogen atmosphere. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford (R)-3-(5-(5,5-dimethyl-1,3,2-dioxaborinan- 2-yl)-1H-indazol-1-yl)-1,1,1-trifluoropropan-2-ol (450 mg, 74% yield) as a yellow oil. LCMS (ESI, m/z): 343 [M+H] + . Synthesis of Intermediate I-5 [0238] A 100 mL round-bottom flask was charged with 4-bromo-1-fluoro-2- nitrobenzene (6.00 g, 27.2 mmol, 1.00 eq.), DMF (24 mL) and 2,2,2-trifluoroethylamine (8.10 g, 81.7 mmol, 3.00 eq.) at rt. The mixture was stirred for 2 days at 100 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (3 x10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford 4-bromo-2-nitro-N-(2,2,2-trifluoroethyl)aniline (8.00 g, 98% yield) as a yellow solid. LCMS (ESI, m/z): 299 [M+H] + . [0239] A mixture of 4-bromo-2-nitro-N-(2,2,2-trifluoroethyl) aniline (8.00 g, 26.7 mmol, 1.00 eq.), iron (14.9 g, 267 mmol, 10.0 eq.) and ammonium chloride (5.72 g, 107 mmol, 4.00 eq.) in EtOH (80 mL) and water (10 mL) was stirred for overnight at 80 °C and then concentrated under reduced pressure. The residue was purified by reverse flash chromatography with the following conditions: column, Agela C 18 Column, 120 g; mobile phase, acetonitrile in water, 0% to 100% gradient in 50 min; detector, UV 254 nm to afford 4-bromo-N1-(2,2,2-trifluoroethyl)benzene-1,2-diamine (6.50 g, 90% yield) as a yellow solid. LCMS (ESI, m/z): 269 [M+H] + . [0240] To a stirred mixture of 4-bromo-N1-(2,2,2-trifluoroethyl) benzene-1,2- diamine (4.50 g, 16.7 mmol, 1.00 eq.) in DMF (50 mL) was added tert-butyl nitrite (3.45 g, 33.4 mmol, 2.00 eq.) at 0 °C. The mixture was stirred for 2 h at 80 °C. The reaction was quenched with water (250 mL). The mixture was extracted with ethyl acetate (3 x 250 mL). The combined organic layers were washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with methanol:dichloromethane (1:10) to afford 5-bromo-1-(2,2,2-trifluoroethyl)-1,2,3-benzotriazole (3.20 g, 68% yield) as a yellow solid. LCMS (ESI, m/z): 280 [M+H] + . [0241] A mixture of 5-bromo-1-(2,2,2-trifluoroethyl)-1,2,3-benzotriazole (3.20 g, 11.4 mmol, 1.00 eq.), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2- dioxaborinane (12.9 g, 57.2 mmol, 5.00 eq.), Pd(PPh 3 ) 2 Cl 2 (0.800 g, 1.14 mmol, 0.10 eq.), potassium acetate (3.36 g, 34.2 mmol, 3.00 eq.) and DMSO (100 mL) was stirred for overnight at 60 °C under a nitrogen atmosphere. The reaction was quenched with water (500 mL). The mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with dichloromethane:methanol (10:1) to afford 5-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d ][1,2,3]triazole (2.10 g, 58% yield) as a white solid. LCMS (ESI, m/z): 314 [M+H] + . Synthesis of Intermediate I-6 [0242] A 100 mL round-bottom flask was charged with 2-fluorobenzonitrile (1.00 g, 8.26 mmol, 1.00 eq.), 4-(trifluoromethyl)-1H-pyrazole (1.12 g, 8.26 mmol, 1.00 eq.), cesium carbonate (5.38 g, 16.5 mmol, 2.00 eq.) and DMF (10 mL). The mixture was stirred for overnight at 60 °C. The reaction was quenched with water (50 mL). The mixture was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with petroleum ether:ethyl acetate (1:1) to afford 2-(4-(trifluoromethyl)-1H-pyrazol-1- yl)benzonitrile (1.50 g, 76% yield) as a white solid. LCMS (ESI, m/z): 238 [M+H] + . [0243] A 100 mL round-bottom flask was charged with 2-[3- (trifluoromethyl)pyrazol-1-yl]benzonitrile (1.10 g, 4.64 mmol, 1.00 eq.), Rany Ni (100 mg) and EtOH (50 mL) at rt. The mixture was stirred for overnight at 60 °C under a hydrogen atmosphere (2-3 atm). The solids were filtered off, and the filter cake was washed with EtOH (3 x 50 mL). The filtrate was concentrated under reduced pressure to afford (2-(3- (trifluoromethyl)-1H-pyrazol-1-yl)phenyl)methanamine (1.00 g, 89% yield) as a colorless oil. LCMS (ESI, m/z): 242 [M+H] + . Synthesis of Intermediate I-7 [0244] A 100 mL round-bottom flask was charged with methyl 2- (aminomethyl)benzoate (2.00 g, 12.1 mmol, 1.00 eq.), Et 3 N (2.45 g, 24.2 mmol, 2.00 eq.), Boc 2 O (5.28 g, 24.2 mmol, 2.00 eq.) and DCM (20 mL). The mixture was stirred for overnight at rt. The reaction was quenched with water (100 mL). The mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (3 x 50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:5) to afford methyl 2-{[(tert- butoxycarbonyl)amino]methyl}benzoate (1.02 g, 32% yield) as a white solid. LCMS (ESI, m/z): 266 [M+H] + . [0245] A 100 mL round-bottom flask was charged with methyl 2-{[(tert- butoxycarbonyl)amino]methyl} benzoate (1.50 g, 5.65 mmol, 1.00 eq.), hydrazine hydrate (0.448 g, 8.96 mmol, 1.58 eq.) and MeOH (10 mL). The mixture was stirred for overnight at 60 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:2) afford tert-butyl N-{[2-(hydrazinecarbonyl) phenyl]methyl} carbamate (1.02 g, 67% yield) as a colorless oil. LCMS (ESI, m/z): 266 [M+H] + . [0246] A 100 mL round-bottom flask was charged with tert-butyl N-{[2- (hydrazinecarbonyl)phenyl]methyl} carbamate (1.10 g, 4.15 mmol, 1.00 eq.) and diethoxy(methoxy)methane (5 mL). The mixture was stirred for overnight at 130 °C. The reaction was quenched with water (20 mL). The mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:2) afford tert-butyl N-{[2-(1,3,4-oxadiazol-2-yl)phenyl]methyl}carbamate (500 mg, 44% yield) as a colorless oil. LCMS (ESI, m/z): 276 [M+H] + . [0247] A 100 mL round-bottom flask were added tert-butyl N-{[2-(1,3,4- oxadiazol-2-yl)phenyl]methyl} carbamate (300 mg, 1.09 mmol, 1.00 eq.), TFA (4 mL) and DCM (20 mL) at rt. The mixture was stirred for 3 h at rt and then concentrated under reduced pressure to afford 1-[2-(1,3,4-oxadiazol-2-yl)phenyl]methanamine trifluoroacetic acid salt (310 mg, crude) as a colorless oil. LCMS (ESI, m/z): 266 [M+H- TFA] + . Synthesis of Intermediate I-8 [0248] A 100 mL round-bottom flask was charged with 2- bromobenzoylhydrazine (10.0 g, 46.5 mmol, 1.00 eq.), phenyl chloroformate (10.9 g, 69.8 mmol, 1.50 eq.), Et 3 N (9.42 g, 93.0 mmol, 2.00 eq.) and THF (100 mL) at rt. The mixture was stirred for 4 h at 0 °C and then concentrated under reduced pressure. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford N'-(2-bromobenzoyl)-1-phenoxyformohydrazide (15.0 g, 96% yield) as a yellow solid. LCMS (ESI, m/z): 335 [M+H] + . [0249] A 250 mL round-bottom flask was charged with N'-(2-bromobenzoyl)-1- phenoxyformohydrazide (15.0 g, 44.8 mmol, 1.00 eq.), CH 3 NH 2 (16.8 g, 179 mmol, 4.00 eq., 33% w/w in MeOH) and MeOH (50 mL). The mixture was stirred for overnight at 60 °C and then concentrated under reduced pressure. The reaction was quenched with water (200 mL). The mixture was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford 2-bromo-N- [(methylcarbamoyl)amino]benzamide (4.60 g, 38% yield) as a white solid. LCMS (ESI, m/z): 272 [M+H] + . [0250] A 250 mL round-bottom flask was charged with 2-bromo-N- [(methylcarbamoyl)amino]benzamide (4.60 g, 16.8 mmol, 1.00 eq.),NaOH (1.34 g, 33.6 mmol, 2.00 eq.) and H 2 O (50 mL). The mixture was stirred for overnight at 100 °C and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (1:1) to afford 5-(2- bromophenyl)-4-methyl-2H-1,2,4-triazol-3-one (3.80 g, 88% yield) as a white solid. LCMS (ESI, m/z): 254 [M+H] + . [0251] A 100 mL vial was charged with 5-(2-bromophenyl)-4-methyl-2H-1,2,4- triazol-3-one (3.80 g, 15.0 mmol, 1.00 eq.), Pd(PPh 3 ) 4 (867 mg, 0.75 mmol, 0.05 eq.), Zn(CN) 2 (3.51 g, 30.0 mmol, 2.00 eq.) and DMF (10 mL). The mixture was irradiated with microwave radiation for 2 h at 180 °C. The reaction was quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH 2 Cl 2 :MeOH (10:1) to afford 2-(4-methyl-5-oxo-1H-1,2,4- triazol-3-yl)benzonitrile (1.01 g, 34% yield) as a white solid. LCMS (ESI, m/z): 201 [M+H] + . [0252] A 250 mL round-bottom flask was charged with 2-(4-methyl-5-oxo-1H- 1,2,4-triazol-3-yl)benzonitrile (1.01 g, 5.05 mmol, 1.00 eq.), LiAlH 4 (960 mg, 25.3 mmol, 5.00 eq.) and THF (100 mL) at rt. The mixture was stirred for overnight at rt. The reaction was quenched with ice/water (960 mg), 30% NaOH (aq., 2.88 g) and water (960 mg). The solids were filtered off, and the filter cake was washed with THF (3x100 mL). The filtrate was concentrated under reduced pressure to afford 5-[2-(aminomethyl)phenyl]-4-methyl-2H- 1,2,4-triazol-3-one (600 mg, crude) as a white solid. LCMS (ESI, m/z): 205 [M+H] + . [0253] A 100 mL round-bottom flask was charged with 5-[2- (aminomethyl)phenyl]-4-methyl-2H-1,2,4-triazol-3-one (600 mg, 2.94 mmol, 1.00 eq.), (Boc) 2 O (1.28 g, 5.88 mmol, 2.00 eq.), Et 3 N (595 mg, 5.88 mmol, 2.00 eq.) and DCM (50 mL). The mixture was stirred for 2 h at rt. The reaction was quenched with water (50 mL). The mixture was extracted with DCM (3 x 200 mL). The combined organic layers were washed with water (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate:petroleum ether (3:1) to afford tert-butyl N-{[2-(4- methyl-5-oxo-1H-1,2,4-triazol-3-yl)phenyl]methyl}carbamate (300 mg, 34% yield) as a white solid. LCMS (ESI, m/z): 305 [M+H] + . [0254] A 100 mL round bottom flask was charged with tert-butyl N-{[2-(4- methyl-5-oxo-1H-1,2,4-triazol-3-yl)phenyl]methyl}carbamate (300 mg, 0.984 mmol, 1.00 eq.), TFA (5 mL) and DCM (20 mL). The mixture was stirred for 2h at rt under an air atmosphere and then concentrated under reduced pressure to provide 5-[2- (aminomethyl)phenyl]-4-methyl-2H-1,2,4-triazol-3-one trifluoroacetic acid salt (310 mg, crude) as a yellow oil. LCMS (ESI, m/z): 205 [M-TFA+H] + . Example 20 [0255] Compounds 4-18 provided in Table A were synthetized using the intermediates and/or protocols of Examples 1-9, using methods and conditions known to those skilled in the art. Enantiomers were obtained from racemic mixtures by preparative chiral HPLC using conditions C1 to C14 described in table B. Enantiomer (a) is the first eluting enantiomer, enantiomer (b) is the second eluting compound.
Table B: Conditions used for the chiral separation of racemic mixtures
Example 17 [0256] Compounds 19-54, 56-70, 72, 74-84, 86-90, 92 and 94-129 provided in Tables C and D were synthetized using the intermediates and/or protocols of Examples 1-16, using methods and conditions known to those skilled in the art. Enantiomers were obtained from racemic mixtures by preparative chiral HPLC or SFC using conditions provided in Table C. Enantiomer (a) is the first eluting enantiomer, enantiomer (b) is the second eluting compound. The chiral centers referred to as rac-(R) or rac-(S) in the compound name have been chosen arbitrarily. Table C
EXAMPLE A HBV-DNA Antiviral Assay using HepG2.117 cells [0257] The following assay procedure describes the HBV antiviral assay, using HepG2.117 cells, which carry a stably integrated genotype D HBV genome under the control of a Tet-off promoter, and intracellular HBV DNA quantification as endpoint. Cell viability is assessed in parallel by measuring the intracellular ATP content using ATPlite (Perkin Elmer). [0258] On day 0, HepG2.117 cells (which are maintained in routine cell culture with doxycycline present in the medium at a final concentration of 1 μg/mL) were seeded in 96-well plates (white with clear bottom) at a density of 2.0 x 10 4 cells/well (0.1 mL/well) in medium without doxycycline to induce pgRNA transcription and subsequent formation of HBV particles. The cells were incubated at 37 °C and 5% CO 2 . [0259] On day 1, medium was removed from each well, the test articles were diluted in culture medium without doxcycyline and 100 μL was added to cell culture wells (9 concentrations, 4-fold dilution). For each plate, 6 untreated (merely DMSO) wells were included. The final concentration of DMSO in the culture medium was 2%. Each plate was prepared in duplicate (one for HBV DNA extraction, one for ATPlite measurement). The cells were incubated at 37 °C and 5% CO 2 for 3 days. The plate map of compound treatment is shown in Figure 1. [0260] On day 4, cell viability was assessed using ATPlite and cell lysates were prepared for HBV DNA extraction and subsequent quantification by qPCR. HBV DNA quantification by qPCR [0261] Medium was removed from each well and 100 μL of 0.33% NP-40 in H 2 O was added to each well. Plates were sealed, incubated at 4 °C for 5 mins, vortexed extensively and centrifuged briefly. Next, 35 μL of lysate was added to 65 μL QuickExtract DNA Extraction Solution (Epicentre) in a PCR plate for each well. PCR plate was incubated at 65 °C for 6 mins, 98 °C for 2 mins and finally cooled to 4 °C. HBV DNA was then quantified by qPCR with HBV-specific primers and probes as specified in Table 1 using the Bio-Rad SSOAdvanced Universal Probes Supermix on a CFX96 machine (Bio-Rad). The PCR cycle program consisted of 95 °C for 3 mins, followed by 40 cycles at 95 °C for 10 sec and 60 °C for 30 sec. Table 1: HBV DNA Primers and Probe for HepG2.117 assay [0262] A DNA standard was prepared by dilution of an IDT gBlock corresponding to the amplicon with concentrations ranging from 10^2 to 10^8 copies/input (i.e. per 4 μL) and used to generate a standard curve by plotting Cq values vs. HBV DNA standard concentration. The quantity of HBV DNA in each sample was determined by interpolating from the standard curve. Cell viability [0263] Using the other plates, the cell viability was quantified by ATPlite according to the manufacturer’s manual. In brief, 50 ^L of cell lysis solution was added to the culture plates and shaken for 5’, followed by addition of 50 ^L substrate into each well and further shaking. The plates were incubated at room temperature for 10 mins and luminescence signal was subsequently measured on a VarioSkan Lux (ThermoFisher) plate reader. Data analysis [0264] Cell viability was calculated as follows: % Cell viability = (luminescence value of test sample) / (average luminescence value of 2% DMSO control) x 100%. HBV DNA inhibition was calculated as follows: 100 - (HBV DNA copy number of test sample) / (average HBV DNA copy number of 2% DMSO control) x 100%. No normalization to entecavir was required due to the excellent dynamic window of this assay. The CC 50 , EC 50 and EC 90 values were determined by dose-response curves fitted using non-linear regression. [0265] As shown in Table 2, compounds of Formula (I) are active against HBV, where ‘A’ indicates an EC 50 ^ 50 nM, ‘B’ indicates an EC 50 > 50 nM and ^ 500 nM, ‘C’ indicates an EC 50 > 500 nM and ^ 5000 nM, and ‘D’ indicates an EC 50 > 5000 nM. Cell viability assessments indicated a large window between effective antiviral concentrations and cytotoxic compound concentrations. Table 2 nd = no data [0266] Although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the present disclosure. Therefore, it should be clearly understood that the forms disclosed herein are illustrative only and are not intended to limit the scope of the present disclosure, but rather to also cover all modification and alternatives coming with the true scope and spirit of the present disclosure.